{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv('/Users/szechan/Documents/a/co_op/clean_los_manual.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "#I want to see all the text in the los column\n",
    "pd.set_option('display.max_colwidth', None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>course_name</th>\n",
       "      <th>folder</th>\n",
       "      <th>title</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC2100.20001.202054</td>\n",
       "      <td>ACC2100 20001 [Canceled] Financial Accounting SEC 01 Summer 2020 CPS [VTL-1-OL]</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC2100.20001.202054</td>\n",
       "      <td>ACC2100 20001 [Canceled] Financial Accounting SEC 01 Summer 2020 CPS [VTL-1-OL]</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC2100.20108.201954</td>\n",
       "      <td>ACC2100 20108 [Canceled] Financial Accounting SEC 03 Summer 2019 CPS [BOS-1-TR]</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              course_id  \\\n",
       "0  ACC2100.20001.202054   \n",
       "1  ACC2100.20001.202054   \n",
       "2  ACC2100.20108.201954   \n",
       "\n",
       "                                                                       course_name  \\\n",
       "0  ACC2100 20001 [Canceled] Financial Accounting SEC 01 Summer 2020 CPS [VTL-1-OL]   \n",
       "1  ACC2100 20001 [Canceled] Financial Accounting SEC 01 Summer 2020 CPS [VTL-1-OL]   \n",
       "2  ACC2100 20108 [Canceled] Financial Accounting SEC 03 Summer 2019 CPS [BOS-1-TR]   \n",
       "\n",
       "                           folder                title  \\\n",
       "0  Week 1: Name weekly topic here  Learning Objectives   \n",
       "1                         Week 2:  Learning Objectives   \n",
       "2  Week 1: Name weekly topic here  Learning Objectives   \n",
       "\n",
       "                                                         main_data  \\\n",
       "0   By the end of the week, you will have the opportunity to:        \n",
       "1   By the end of the week, you will have the opportunity to:        \n",
       "2   By the end of the week, you will have the opportunity to:        \n",
       "\n",
       "                                                                                       los  \n",
       "0   By the end of the week, you will have the opportunity to:                               \n",
       "1   By the end of the week, you will have the opportunity to:                               \n",
       "2   By the end of the week, you will have the opportunity to:                               "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(58897, 6)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Create a copy \n",
    "df1 = df.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Make sure there is no space in the column names\n",
    "df1.columns = df1.columns.str.strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# We only need the course id(without CRN and term) (example: ALY6000)\n",
    "df1['course_id'] = df1['course_id'].str.slice(0, -13)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Making sure the change is reflected in the df1 dataframe\n",
    "df1.drop(['course_name'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>title</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3216</th>\n",
       "      <td>ALY6060</td>\n",
       "      <td>Week 5: Analytics and (Business) Performance</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to    understand the use of Tableau using a specific data set in the course of an analytics tools application lab.</td>\n",
       "      <td>By the end of the week, you will have the opportunity to    understand the use of Tableau using a specific data set in the course of an analytics tools application lab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14391</th>\n",
       "      <td>DGM6461</td>\n",
       "      <td>Week 12: Design-a-thon!</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Work through a real-life design process in class    \\n   Collaborate in a team group and pool ideas   \\n   Critique and q uestion classmates about their projects and discuss the different approaches each student may have taken  \\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |    Work through a real-life design process in class     |    Collaborate in a team group and pool ideas    |    Critique and q uestion classmates about their projects and discuss the different approaches each student may have taken   |</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      course_id                                        folder  \\\n",
       "3216    ALY6060  Week 5: Analytics and (Business) Performance   \n",
       "14391   DGM6461                       Week 12: Design-a-thon!   \n",
       "\n",
       "                     title  \\\n",
       "3216   Learning Objectives   \n",
       "14391  Learning Objectives   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                            main_data  \\\n",
       "3216                                                                                                                                     By the end of the week, you will have the opportunity to    understand the use of Tableau using a specific data set in the course of an analytics tools application lab.       \n",
       "14391    By the end of the week, you will have the opportunity to:   \\n  \\n   Work through a real-life design process in class    \\n   Collaborate in a team group and pool ideas   \\n   Critique and q uestion classmates about their projects and discuss the different approaches each student may have taken  \\n    \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                               los  \n",
       "3216                                                                                                                                          By the end of the week, you will have the opportunity to    understand the use of Tableau using a specific data set in the course of an analytics tools application lab.                              \n",
       "14391    By the end of the week, you will have the opportunity to:    |    |    Work through a real-life design process in class     |    Collaborate in a team group and pool ideas    |    Critique and q uestion classmates about their projects and discuss the different approaches each student may have taken   |                            "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1.sample(n=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "df2 = df1['los'].str.split(('( ?\\| ?)+'), expand=True) \n",
    "df2.columns = ['los{}'.format(x+1) for x in df2.columns] \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>los1</th>\n",
       "      <th>los2</th>\n",
       "      <th>los3</th>\n",
       "      <th>los4</th>\n",
       "      <th>los5</th>\n",
       "      <th>los6</th>\n",
       "      <th>los7</th>\n",
       "      <th>los8</th>\n",
       "      <th>los9</th>\n",
       "      <th>los10</th>\n",
       "      <th>...</th>\n",
       "      <th>los780</th>\n",
       "      <th>los781</th>\n",
       "      <th>los782</th>\n",
       "      <th>los783</th>\n",
       "      <th>los784</th>\n",
       "      <th>los785</th>\n",
       "      <th>los786</th>\n",
       "      <th>los787</th>\n",
       "      <th>los788</th>\n",
       "      <th>los789</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>36386</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>By the end of the week, you will have the opportunity to</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47873</th>\n",
       "      <td>By the end of the week, you should be able to:        know the terms and concepts associated with electric current, resistance, voltage,  and power; DC   AC   analize situations involving electric current, resistance, voltage,  and power; DC   AC  solve problems involving  electric current, resistance, voltage,  and power; DC   AC</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Analyze the effect of business transactions on the basic accounting equation.</td>\n",
       "      <td>|</td>\n",
       "      <td>Explain how accounts, debits, and credits are used to record business transactions.</td>\n",
       "      <td>|</td>\n",
       "      <td>Indicate how a journal is used in the recording process  .</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36896</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:    Identify the skills and requirements for information security positions   List the various information security professional certifications, and identify which skills are encompassed by each   Discuss and implement information security constraints on the general hiring processes   Explain the role of information security in employee terminations   Describe the security practices used to control employee behavior and prevent misuse of information  Differentiate between law and ethics   Describe the ethical foundations and approaches that underlie modern codes of ethics   Identify major national and international laws that relate to the practice of information security   Describe the role of culture as it applies to ethics in information security   Identify current information on laws, regulations, and relevant professional organizations</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34620</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Work with Datasets</td>\n",
       "      <td>|</td>\n",
       "      <td>Convert Excel to Tables</td>\n",
       "      <td>|</td>\n",
       "      <td>Learn how to manipulate tables</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6851</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Module Overview</td>\n",
       "      <td>|</td>\n",
       "      <td>Time to event analyses - Survival Analysis, are often used in medical and epidemiological research. Some examples include the median time to death after being diagnosed with a heart condition or estimating time to infection after exposure to disease.What to Do This Week</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48709</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Explain the monitoring and controlling process group</td>\n",
       "      <td>|</td>\n",
       "      <td>Identify the most common tools and techniques used in monitoring and controlling projects</td>\n",
       "      <td>|</td>\n",
       "      <td>Demonstrate an understanding of basic earned value concepts</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1190</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Described the motives and methods for business combinations</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21970</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5129</th>\n",
       "      <td>By the end of the week, you will have the opportunity to bring together what you have learned in this course and apply it at a real case study.</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50872</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Define Control Quality</td>\n",
       "      <td>|</td>\n",
       "      <td>Identify the inputs, tools, techniques, and outputs of the Control Quality process</td>\n",
       "      <td>|</td>\n",
       "      <td>Explain the difference between prevention and inspection</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34847</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Describe implementation and deployment activities</td>\n",
       "      <td>|</td>\n",
       "      <td>Describe the four types of software tests and explain how and why each is used</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54156</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33285</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2943</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14260</th>\n",
       "      <td>By the end of this section, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Finish your project.</td>\n",
       "      <td>|</td>\n",
       "      <td>Create screenshots, gameplay videos, descriptions, and any other materials for your project's webpage.</td>\n",
       "      <td>|</td>\n",
       "      <td>Publish your project online.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40629</th>\n",
       "      <td>In relation to Web Portfolios, this week you will have the opportunity to:                               Analyze Requirements and Standards                               Analyze Purposes and Goals                               Analyze Audiences                               Decide what to Include                               Decide what to Revise                               Create a Web Portfolio Plan</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45862</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Distinguish between the different marketing communications channels</td>\n",
       "      <td>|</td>\n",
       "      <td>Understand the importance of Audience - Centric Communications</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30895</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Have an understanding of the General A  viation   S  ystem   and how it compares to Commercial Aviation</td>\n",
       "      <td>|</td>\n",
       "      <td>Have an understanding of the security programs specific to General Aviation</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8101</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Wage differential in Labor Markets:</td>\n",
       "      <td>|</td>\n",
       "      <td>State and Nature of wage differentials</td>\n",
       "      <td>|</td>\n",
       "      <td>Causes of Wage Differentials</td>\n",
       "      <td>|</td>\n",
       "      <td>Labor Policies and Wage Diffferentials</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52013</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Evaluate and provide feedback to peer Program deliverables</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Create strategies for addressing environmental, technical and organizational complexity when implementing program by t      ailoring    / applying advanced program management concepts to a program exercise/reflection</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37060</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:   Identify and describe the stages of the risk management lifecycle and process flow  Recognize the differences between what is meant by vulnerability assessment and risk assessment  Begin to make decisions based on risk assessment and evaluation  Educate others regarding their responsibilities to protect their own information resources  Describe and define those roles and responsibilities for business owners and information security personnel  Apply risk analysis techniques and strategies   Understand and develop your own security risk profile</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46600</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Identify and evaluate the pros and cons of at least three methods of visual support for educational sessions</td>\n",
       "      <td>|</td>\n",
       "      <td>Describe at least five technical guidelines for designing effective, audience-appropriate educational materials</td>\n",
       "      <td>|</td>\n",
       "      <td>Confirm the theory you   wi  ll use as the foundation of your final project</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48391</th>\n",
       "      <td>By the end of the week, you should be able to: Identify and describe the project management process groups</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Identify and describe the processes involved in the  Initiating Process Group</td>\n",
       "      <td>|</td>\n",
       "      <td>Explain the importance of using best practices to initiate a project</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13172</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>-Identify the 3 types of linear perspective.</td>\n",
       "      <td>|</td>\n",
       "      <td>-Understand the role of the horizon line, vanishing point   guidelines.</td>\n",
       "      <td>|</td>\n",
       "      <td>-Accurately draw and represent the principles of one point   two point perspective.</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23973</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23266</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>898</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Explore market-based valuation multiples</td>\n",
       "      <td>|</td>\n",
       "      <td>Compare and contrast the MB Ratio with the VB Ratio</td>\n",
       "      <td>|</td>\n",
       "      <td>Compare and contrast the PE Ratio with the PEG Ratio</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57871</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Consider the different research methods used by Sociologists.</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4946</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>learn how to write a quantitative or mixed methods research proposal</td>\n",
       "      <td>|</td>\n",
       "      <td>practice writing literature reviews</td>\n",
       "      <td>|</td>\n",
       "      <td>practice experential learning</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35240</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Design a network, specifying appropriate topologies and hardware to address a specificbusiness environment and its network needs.</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>ÔÇ∑ Identify and explain the functions of the core TCP/IP protocols.ÔÇ∑ Compare the characteristics of WAN technologies, including their switching type, throughput,media, security, and reliability.</td>\n",
       "      <td>|</td>\n",
       "      <td>ÔÇ∑ Create and configure virtual servers, adapters, and switches as part of a network.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43165</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Study contract formation</td>\n",
       "      <td>|</td>\n",
       "      <td>Learn about the rules of law related to performance and breach of a contract</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33920</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Continue Experiential Network (XN) project work</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52209</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Evaluate the routine project planning processes, to provide context for the planning done in Scrum</td>\n",
       "      <td>|</td>\n",
       "      <td>Create an understanding of the five levels of planning done inside Scrum</td>\n",
       "      <td>|</td>\n",
       "      <td>Create an understanding of how Agile projects must be integrated into the larger corporate project environment</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26342</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>(Chapter 9)</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Define the sources of capital.</td>\n",
       "      <td>|</td>\n",
       "      <td>Define and calculate the marginal cost of capital.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33097</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Explore the diverse range of clients and settings within Human Services</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21265</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>By the end of the week, you will be able to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40359</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56131</th>\n",
       "      <td>By the end of this week you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Describe the Australian Medical device system</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56032</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Learn about the history of the European Union formation and organizational structure.</td>\n",
       "      <td>|</td>\n",
       "      <td>Understand the structure and function of the European Medicines Agency (EMA).</td>\n",
       "      <td>|</td>\n",
       "      <td>Obtain a working knowledge of the regulatory document hierarchy in the EU.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58315</th>\n",
       "      <td>By the end of the week, you will have the opportunity to learn about:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>The importance of oral communication</td>\n",
       "      <td>|</td>\n",
       "      <td>Tips for video, tele- and webconferences</td>\n",
       "      <td>|</td>\n",
       "      <td>Parts of an oral presentation</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58088</th>\n",
       "      <td>In this lesson and chapter we will focus on:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>History of Hallucinogens</td>\n",
       "      <td>|</td>\n",
       "      <td>Effects of Hallucinogens</td>\n",
       "      <td>|</td>\n",
       "      <td>Natural Substances</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55981</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Understand that OPDP recommends the drug's indication and risk information be communicated in patient-friendly language and review an FDA Guidance recommending the creation of patient-friendly brief summaries for printed ads.</td>\n",
       "      <td>|</td>\n",
       "      <td>Learn that DTC materials should clearly indicate that only a prescribing healthcare professional can determine whether a particular prescribing drug is appropriate for a patient.</td>\n",
       "      <td>|</td>\n",
       "      <td>Understand that DTC broadcast advertisements are required to communicate the major statement of a drug's risk in a clear, conspicuous and neutral manner and review an OPDP draft regulation defining these terms.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22035</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30624</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>Understand the relationship between civilian and government systems</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33140</th>\n",
       "      <td>By the end of the week, you will have had the opportunity to:       Review change management strategies     Practice force field analysis in change management    Understand mistakes managers make in managing change    Consider the importance of being flexible in our approach</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38747</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3513</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>explain what  research  questions the authors are trying to answer with dashboards;</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36283</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Explore and understand the purpose of an EA Management Plan.</td>\n",
       "      <td>|</td>\n",
       "      <td>Explore example formats for an EA Management Plan..</td>\n",
       "      <td>|</td>\n",
       "      <td>Identify and explain the types of content that go into an EA Management Plan.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35044</th>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>When students have finished reading this chapter, they will be able to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Create a Query with a Calculated Field</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1385</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10594</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Identify five principles of effective crisis communication</td>\n",
       "      <td>|</td>\n",
       "      <td>Explain the relevance of these principles to organizations and organizational health</td>\n",
       "      <td>|</td>\n",
       "      <td>Several case studies relating to the principles of crisis communication</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1119</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>Chapter 13</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Use the five types of audit tests to determine whether financial statements are fairly stated.</td>\n",
       "      <td>|</td>\n",
       "      <td>Select the appropriate types of audit tests.</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28946</th>\n",
       "      <td>By the end of this week you will be able to:</td>\n",
       "      <td>|</td>\n",
       "      <td>Explain the peacebuilding as an international necessity and responsibility and that liberal peacebuilding aims to create a state defined by the rule of law, markets, and democracy.</td>\n",
       "      <td>|</td>\n",
       "      <td>Describe the objectives and goals of military intervention on the example of NATO's Libya campaign and other cases.</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10999</th>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Become more familiar with the art of storytelling for compelling presentations</td>\n",
       "      <td>|</td>\n",
       "      <td>Prepare an individual presentation</td>\n",
       "      <td>|</td>\n",
       "      <td>Work with a partner to provide feedback on each others' presentations</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>55 rows × 789 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             los1  \\\n",
       "36386                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
       "47873                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you should be able to:        know the terms and concepts associated with electric current, resistance, voltage,  and power; DC   AC   analize situations involving electric current, resistance, voltage,  and power; DC   AC  solve problems involving  electric current, resistance, voltage,  and power; DC   AC                               \n",
       "60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   By the end of the week, you will have the opportunity to:      \n",
       "36896   By the end of the week, you will have the opportunity to:    Identify the skills and requirements for information security positions   List the various information security professional certifications, and identify which skills are encompassed by each   Discuss and implement information security constraints on the general hiring processes   Explain the role of information security in employee terminations   Describe the security practices used to control employee behavior and prevent misuse of information  Differentiate between law and ethics   Describe the ethical foundations and approaches that underlie modern codes of ethics   Identify major national and international laws that relate to the practice of information security   Describe the role of culture as it applies to ethics in information security   Identify current information on laws, regulations, and relevant professional organizations                                \n",
       "34620                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "6851                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
       "48709                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "1190                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:      \n",
       "21970                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "5129                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you will have the opportunity to bring together what you have learned in this course and apply it at a real case study.                             \n",
       "50872                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               By the end of the week, you will have the opportunity to:       \n",
       "34847                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "54156                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "33285                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "2943                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of the week, you will have the opportunity to:                                \n",
       "14260                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            By the end of this section, you will have the opportunity to:      \n",
       "40629                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           In relation to Web Portfolios, this week you will have the opportunity to:                               Analyze Requirements and Standards                               Analyze Purposes and Goals                               Analyze Audiences                               Decide what to Include                               Decide what to Revise                               Create a Web Portfolio Plan                             \n",
       "45862                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "30895                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "8101                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
       "52013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "37060                                                                                                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:   Identify and describe the stages of the risk management lifecycle and process flow  Recognize the differences between what is meant by vulnerability assessment and risk assessment  Begin to make decisions based on risk assessment and evaluation  Educate others regarding their responsibilities to protect their own information resources  Describe and define those roles and responsibilities for business owners and information security personnel  Apply risk analysis techniques and strategies   Understand and develop your own security risk profile                             \n",
       "46600                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "48391                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you should be able to: Identify and describe the project management process groups     \n",
       "13172                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "23973                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "23266                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "898                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:      \n",
       "57871                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "4946                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:      \n",
       "35240                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
       "43165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "33920                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "52209                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               By the end of the week, you will have the opportunity to:       \n",
       "26342                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "33097                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "21265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
       "40359                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               By the end of the week, you will have the opportunity to:       \n",
       "56131                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              By the end of this week you will have the opportunity to:        \n",
       "56032                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "58315                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you will have the opportunity to learn about:      \n",
       "58088                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              In this lesson and chapter we will focus on:     \n",
       "55981                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "22035                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "30624                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:     \n",
       "33140                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            By the end of the week, you will have had the opportunity to:       Review change management strategies     Practice force field analysis in change management    Understand mistakes managers make in managing change    Consider the importance of being flexible in our approach                                \n",
       "38747                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to:                                \n",
       "3513                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:      \n",
       "36283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "35044                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
       "1385                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of the week, you will have the opportunity to:                                \n",
       "10594                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "1119                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 By the end of the week, you will have the opportunity to:      \n",
       "28946                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           By the end of this week you will be able to:        \n",
       "10999                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:      \n",
       "\n",
       "       los2  \\\n",
       "36386    |    \n",
       "47873  None   \n",
       "60       |    \n",
       "36896  None   \n",
       "34620    |    \n",
       "6851     |    \n",
       "48709    |    \n",
       "1190     |    \n",
       "21970  None   \n",
       "5129   None   \n",
       "50872    |    \n",
       "34847    |    \n",
       "54156  None   \n",
       "33285  None   \n",
       "2943   None   \n",
       "14260    |    \n",
       "40629  None   \n",
       "45862    |    \n",
       "30895    |    \n",
       "8101     |    \n",
       "52013    |    \n",
       "37060  None   \n",
       "46600    |    \n",
       "48391    |    \n",
       "13172    |    \n",
       "23973  None   \n",
       "23266  None   \n",
       "898      |    \n",
       "57871    |    \n",
       "4946     |    \n",
       "35240    |    \n",
       "43165    |    \n",
       "33920    |    \n",
       "52209    |    \n",
       "26342    |    \n",
       "33097    |    \n",
       "21265    |    \n",
       "40359    |    \n",
       "56131    |    \n",
       "56032    |    \n",
       "58315    |    \n",
       "58088    |    \n",
       "55981    |    \n",
       "22035  None   \n",
       "30624    |    \n",
       "33140  None   \n",
       "38747  None   \n",
       "3513     |    \n",
       "36283    |    \n",
       "35044    |    \n",
       "1385   None   \n",
       "10594    |    \n",
       "1119     |    \n",
       "28946    |    \n",
       "10999    |    \n",
       "\n",
       "                                                                                                                                                                                               los3  \\\n",
       "36386                                                                                                                                                                                                 \n",
       "47873                                                                                                                                                                                          None   \n",
       "60                                                                                                                                                                                                    \n",
       "36896                                                                                                                                                                                          None   \n",
       "34620                                                                                                                                                                                                 \n",
       "6851                                                                                                                                                                                                  \n",
       "48709                                                                                                                                                                                                 \n",
       "1190                                                                                                                                                                                                  \n",
       "21970                                                                                                                                                                                          None   \n",
       "5129                                                                                                                                                                                           None   \n",
       "50872                                                                                                                                                                                                 \n",
       "34847                                                                                                                                                                                                 \n",
       "54156                                                                                                                                                                                          None   \n",
       "33285                                                                                                                                                                                          None   \n",
       "2943                                                                                                                                                                                           None   \n",
       "14260                                                                                                                                                                                                 \n",
       "40629                                                                                                                                                                                          None   \n",
       "45862                                                                                                                                                                                                 \n",
       "30895                                                                                                                                                                                                 \n",
       "8101                                                                                                                                                          Wage differential in Labor Markets:     \n",
       "52013                                                                                                                                                                                                 \n",
       "37060                                                                                                                                                                                          None   \n",
       "46600                                                                                                                                                                                                 \n",
       "48391                                                                                                                                                                                                 \n",
       "13172                                                                                                                                                -Identify the 3 types of linear perspective.     \n",
       "23973                                                                                                                                                                                          None   \n",
       "23266                                                                                                                                                                                          None   \n",
       "898                                                                                                                                                                                                   \n",
       "57871                                                                                                                                                                                                 \n",
       "4946                                                                                                                                                                                                  \n",
       "35240                                                           Design a network, specifying appropriate topologies and hardware to address a specificbusiness environment and its network needs.     \n",
       "43165                                                                                                                                                                                                 \n",
       "33920                                                                                                                                                                                                 \n",
       "52209                                                                                                                                                                                                 \n",
       "26342                                                                                                                                                                                  (Chapter 9)    \n",
       "33097                                                                                                                                                                                                 \n",
       "21265                                                                                                                                                                                                 \n",
       "40359                                                                                                                                                                                                 \n",
       "56131                                                                                                                                                                                                 \n",
       "56032                                                                                                                                                                                                 \n",
       "58315                                                                                                                                                                                                 \n",
       "58088                                                                                                                                                                                                 \n",
       "55981                                                                                                                                                                                                 \n",
       "22035                                                                                                                                                                                          None   \n",
       "30624                                                                                                 Understand the relationship between civilian and government systems                             \n",
       "33140                                                                                                                                                                                          None   \n",
       "38747                                                                                                                                                                                          None   \n",
       "3513                                                                                                                                                                                                  \n",
       "36283                                                                                                                                                                                                 \n",
       "35044                                                                                                                      When students have finished reading this chapter, they will be able to:    \n",
       "1385                                                                                                                                                                                           None   \n",
       "10594                                                                                                                                                                                                 \n",
       "1119                                                                                                                                                                                  Chapter 13      \n",
       "28946      Explain the peacebuilding as an international necessity and responsibility and that liberal peacebuilding aims to create a state defined by the rule of law, markets, and democracy.       \n",
       "10999                                                                                                                                                                                                 \n",
       "\n",
       "       los4  \\\n",
       "36386    |    \n",
       "47873  None   \n",
       "60       |    \n",
       "36896  None   \n",
       "34620    |    \n",
       "6851     |    \n",
       "48709    |    \n",
       "1190     |    \n",
       "21970  None   \n",
       "5129   None   \n",
       "50872    |    \n",
       "34847    |    \n",
       "54156  None   \n",
       "33285  None   \n",
       "2943   None   \n",
       "14260    |    \n",
       "40629  None   \n",
       "45862    |    \n",
       "30895    |    \n",
       "8101     |    \n",
       "52013    |    \n",
       "37060  None   \n",
       "46600    |    \n",
       "48391    |    \n",
       "13172    |    \n",
       "23973  None   \n",
       "23266  None   \n",
       "898      |    \n",
       "57871    |    \n",
       "4946     |    \n",
       "35240    |    \n",
       "43165    |    \n",
       "33920    |    \n",
       "52209    |    \n",
       "26342    |    \n",
       "33097    |    \n",
       "21265    |    \n",
       "40359    |    \n",
       "56131    |    \n",
       "56032    |    \n",
       "58315    |    \n",
       "58088    |    \n",
       "55981    |    \n",
       "22035  None   \n",
       "30624  None   \n",
       "33140  None   \n",
       "38747  None   \n",
       "3513     |    \n",
       "36283    |    \n",
       "35044    |    \n",
       "1385   None   \n",
       "10594    |    \n",
       "1119     |    \n",
       "28946    |    \n",
       "10999    |    \n",
       "\n",
       "                                                                                                                                                                                                                                          los5  \\\n",
       "36386                                                                                                                                                                              By the end of the week, you will have the opportunity to      \n",
       "47873                                                                                                                                                                                                                                     None   \n",
       "60                                                                                                                                                            Analyze the effect of business transactions on the basic accounting equation.      \n",
       "36896                                                                                                                                                                                                                                     None   \n",
       "34620                                                                                                                                                                                                                     Work with Datasets     \n",
       "6851                                                                                                                                                                                                                         Module Overview     \n",
       "48709                                                                                                                                                                                   Explain the monitoring and controlling process group     \n",
       "1190                                                                                                                                                                             Described the motives and methods for business combinations     \n",
       "21970                                                                                                                                                                                                                                     None   \n",
       "5129                                                                                                                                                                                                                                      None   \n",
       "50872                                                                                                                                                                                                                Define Control Quality      \n",
       "34847                                                                                                                                                                                                                                            \n",
       "54156                                                                                                                                                                                                                                     None   \n",
       "33285                                                                                                                                                                                                                                     None   \n",
       "2943                                                                                                                                                                                                                                      None   \n",
       "14260                                                                                                                                                                                                                   Finish your project.     \n",
       "40629                                                                                                                                                                                                                                     None   \n",
       "45862                                                                                                                                                                                                                                            \n",
       "30895                                                                                                                                Have an understanding of the General A  viation   S  ystem   and how it compares to Commercial Aviation     \n",
       "8101                                                                                                                                                                                                  State and Nature of wage differentials     \n",
       "52013                                                                                                                                                                             Evaluate and provide feedback to peer Program deliverables     \n",
       "37060                                                                                                                                                                                                                                     None   \n",
       "46600                                                                                                                            Identify and evaluate the pros and cons of at least three methods of visual support for educational sessions    \n",
       "48391                                                                                                                                                                                                                                            \n",
       "13172                                                                                                                                                                -Understand the role of the horizon line, vanishing point   guidelines.     \n",
       "23973                                                                                                                                                                                                                                     None   \n",
       "23266                                                                                                                                                                                                                                     None   \n",
       "898                                                                                                                                                                                                 Explore market-based valuation multiples     \n",
       "57871                                                                                                                                                                          Consider the different research methods used by Sociologists.     \n",
       "4946                                                                                                                                                                    learn how to write a quantitative or mixed methods research proposal     \n",
       "35240                                                                                                                                                                                                                                            \n",
       "43165                                                                                                                                                                                                                Study contract formation    \n",
       "33920                                                                                                                                                                                        Continue Experiential Network (XN) project work     \n",
       "52209                                                                                                                                    Evaluate the routine project planning processes, to provide context for the planning done in Scrum      \n",
       "26342                                                                                                                                                                                                                                            \n",
       "33097                                                                                                                                                                                                                                            \n",
       "21265                                                                                                                                                                                                                                            \n",
       "40359                                                                                                                                                                                                                                            \n",
       "56131                                                                                                                                                                                                                                            \n",
       "56032                                                                                                                                                 Learn about the history of the European Union formation and organizational structure.      \n",
       "58315                                                                                                                                                                                                   The importance of oral communication     \n",
       "58088                                                                                                                                                                                                               History of Hallucinogens     \n",
       "55981     Understand that OPDP recommends the drug's indication and risk information be communicated in patient-friendly language and review an FDA Guidance recommending the creation of patient-friendly brief summaries for printed ads.      \n",
       "22035                                                                                                                                                                                                                                     None   \n",
       "30624                                                                                                                                                                                                                                     None   \n",
       "33140                                                                                                                                                                                                                                     None   \n",
       "38747                                                                                                                                                                                                                                     None   \n",
       "3513                                                                                                                                                                                                                                             \n",
       "36283                                                                                                                                                                           Explore and understand the purpose of an EA Management Plan.     \n",
       "35044                                                                                                                                                                                                                                            \n",
       "1385                                                                                                                                                                                                                                      None   \n",
       "10594                                                                                                                                                                             Identify five principles of effective crisis communication     \n",
       "1119                                                                                                                                                                                                                                             \n",
       "28946                                                                                                                  Describe the objectives and goals of military intervention on the example of NATO's Libya campaign and other cases.       \n",
       "10999                                                                                                                                                         Become more familiar with the art of storytelling for compelling presentations     \n",
       "\n",
       "       los6  \\\n",
       "36386    |    \n",
       "47873  None   \n",
       "60       |    \n",
       "36896  None   \n",
       "34620    |    \n",
       "6851     |    \n",
       "48709    |    \n",
       "1190     |    \n",
       "21970  None   \n",
       "5129   None   \n",
       "50872    |    \n",
       "34847    |    \n",
       "54156  None   \n",
       "33285  None   \n",
       "2943   None   \n",
       "14260    |    \n",
       "40629  None   \n",
       "45862    |    \n",
       "30895    |    \n",
       "8101     |    \n",
       "52013    |    \n",
       "37060  None   \n",
       "46600    |    \n",
       "48391    |    \n",
       "13172    |    \n",
       "23973  None   \n",
       "23266  None   \n",
       "898      |    \n",
       "57871    |    \n",
       "4946     |    \n",
       "35240    |    \n",
       "43165    |    \n",
       "33920    |    \n",
       "52209    |    \n",
       "26342    |    \n",
       "33097    |    \n",
       "21265    |    \n",
       "40359    |    \n",
       "56131    |    \n",
       "56032    |    \n",
       "58315    |    \n",
       "58088    |    \n",
       "55981    |    \n",
       "22035  None   \n",
       "30624  None   \n",
       "33140  None   \n",
       "38747  None   \n",
       "3513     |    \n",
       "36283    |    \n",
       "35044    |    \n",
       "1385   None   \n",
       "10594    |    \n",
       "1119     |    \n",
       "28946    |    \n",
       "10999    |    \n",
       "\n",
       "                                                                                                                                                                                                                                                                                      los7  \\\n",
       "36386                                                                                                                                                                                                                                                                                        \n",
       "47873                                                                                                                                                                                                                                                                                 None   \n",
       "60                                                                                                                                                                                                  Explain how accounts, debits, and credits are used to record business transactions.      \n",
       "36896                                                                                                                                                                                                                                                                                 None   \n",
       "34620                                                                                                                                                                                                                                                            Convert Excel to Tables     \n",
       "6851      Time to event analyses - Survival Analysis, are often used in medical and epidemiological research. Some examples include the median time to death after being diagnosed with a heart condition or estimating time to infection after exposure to disease.What to Do This Week     \n",
       "48709                                                                                                                                                                                          Identify the most common tools and techniques used in monitoring and controlling projects     \n",
       "1190                                                                                                                                                                                                                                                                                         \n",
       "21970                                                                                                                                                                                                                                                                                 None   \n",
       "5129                                                                                                                                                                                                                                                                                  None   \n",
       "50872                                                                                                                                                                                                Identify the inputs, tools, techniques, and outputs of the Control Quality process      \n",
       "34847                                                                                                                                                                                                                                  Describe implementation and deployment activities     \n",
       "54156                                                                                                                                                                                                                                                                                 None   \n",
       "33285                                                                                                                                                                                                                                                                                 None   \n",
       "2943                                                                                                                                                                                                                                                                                  None   \n",
       "14260                                                                                                                                                                             Create screenshots, gameplay videos, descriptions, and any other materials for your project's webpage.     \n",
       "40629                                                                                                                                                                                                                                                                                 None   \n",
       "45862                                                                                                                                                                                                               Distinguish between the different marketing communications channels      \n",
       "30895                                                                                                                                                                                                         Have an understanding of the security programs specific to General Aviation    \n",
       "8101                                                                                                                                                                                                                                                        Causes of Wage Differentials     \n",
       "52013                                                                                                                                                                                                                                                                                        \n",
       "37060                                                                                                                                                                                                                                                                                 None   \n",
       "46600                                                                                                                                                                     Describe at least five technical guidelines for designing effective, audience-appropriate educational materials    \n",
       "48391                                                                                                                                                                                                     Identify and describe the processes involved in the  Initiating Process Group      \n",
       "13172                                                                                                                                                                        -Accurately draw and represent the principles of one point   two point perspective.                             \n",
       "23973                                                                                                                                                                                                                                                                                 None   \n",
       "23266                                                                                                                                                                                                                                                                                 None   \n",
       "898                                                                                                                                                                                                                                  Compare and contrast the MB Ratio with the VB Ratio     \n",
       "57871                                                                                                                                                                                                                                                                                        \n",
       "4946                                                                                                                                                                                                                                                 practice writing literature reviews     \n",
       "35240                                                                              ÔÇ∑ Identify and explain the functions of the core TCP/IP protocols.ÔÇ∑ Compare the characteristics of WAN technologies, including their switching type, throughput,media, security, and reliability.     \n",
       "43165                                                                                                                                                                                                        Learn about the rules of law related to performance and breach of a contract    \n",
       "33920                                                                                                                                                                                                                                                                                        \n",
       "52209                                                                                                                                                                                                           Create an understanding of the five levels of planning done inside Scrum     \n",
       "26342                                                                                                                                                                                                                                                      Define the sources of capital.    \n",
       "33097                                                                                                                                                                                                          Explore the diverse range of clients and settings within Human Services       \n",
       "21265                                                                                                                                                                                                                                       By the end of the week, you will be able to:     \n",
       "40359                                                                                                                                                                                                                                                                                        \n",
       "56131                                                                                                                                                                                                                                                                                        \n",
       "56032                                                                                                                                                                                                     Understand the structure and function of the European Medicines Agency (EMA).      \n",
       "58315                                                                                                                                                                                                                                           Tips for video, tele- and webconferences     \n",
       "58088                                                                                                                                                                                                                                                           Effects of Hallucinogens     \n",
       "55981                                                                                                Learn that DTC materials should clearly indicate that only a prescribing healthcare professional can determine whether a particular prescribing drug is appropriate for a patient.      \n",
       "22035                                                                                                                                                                                                                                                                                 None   \n",
       "30624                                                                                                                                                                                                                                                                                 None   \n",
       "33140                                                                                                                                                                                                                                                                                 None   \n",
       "38747                                                                                                                                                                                                                                                                                 None   \n",
       "3513                                                                                                                                                                                                                                                                                         \n",
       "36283                                                                                                                                                                                                                                Explore example formats for an EA Management Plan..     \n",
       "35044                                                                                                                                                                                                                                                                                        \n",
       "1385                                                                                                                                                                                                                                                                                  None   \n",
       "10594                                                                                                                                                                                               Explain the relevance of these principles to organizations and organizational health     \n",
       "1119                                                                                                                                                                                     Use the five types of audit tests to determine whether financial statements are fairly stated.      \n",
       "28946                                                                                                                                                                                                                                                                                        \n",
       "10999                                                                                                                                                                                                                                                 Prepare an individual presentation     \n",
       "\n",
       "       los8  \\\n",
       "36386    |    \n",
       "47873  None   \n",
       "60       |    \n",
       "36896  None   \n",
       "34620    |    \n",
       "6851     |    \n",
       "48709    |    \n",
       "1190   None   \n",
       "21970  None   \n",
       "5129   None   \n",
       "50872    |    \n",
       "34847    |    \n",
       "54156  None   \n",
       "33285  None   \n",
       "2943   None   \n",
       "14260    |    \n",
       "40629  None   \n",
       "45862    |    \n",
       "30895    |    \n",
       "8101     |    \n",
       "52013    |    \n",
       "37060  None   \n",
       "46600    |    \n",
       "48391    |    \n",
       "13172  None   \n",
       "23973  None   \n",
       "23266  None   \n",
       "898      |    \n",
       "57871  None   \n",
       "4946     |    \n",
       "35240    |    \n",
       "43165    |    \n",
       "33920    |    \n",
       "52209    |    \n",
       "26342    |    \n",
       "33097    |    \n",
       "21265    |    \n",
       "40359    |    \n",
       "56131    |    \n",
       "56032    |    \n",
       "58315    |    \n",
       "58088    |    \n",
       "55981    |    \n",
       "22035  None   \n",
       "30624  None   \n",
       "33140  None   \n",
       "38747  None   \n",
       "3513     |    \n",
       "36283    |    \n",
       "35044    |    \n",
       "1385   None   \n",
       "10594    |    \n",
       "1119     |    \n",
       "28946  None   \n",
       "10999    |    \n",
       "\n",
       "                                                                                                                                                                                                                               los9  \\\n",
       "36386                                                                                                                                                                                                                                 \n",
       "47873                                                                                                                                                                                                                          None   \n",
       "60                                                                                                                                                                    Indicate how a journal is used in the recording process  .      \n",
       "36896                                                                                                                                                                                                                          None   \n",
       "34620                                                                                                                                                                                              Learn how to manipulate tables     \n",
       "6851                                                                                                                                                                                                                                  \n",
       "48709                                                                                                                                                                 Demonstrate an understanding of basic earned value concepts     \n",
       "1190                                                                                                                                                                                                                           None   \n",
       "21970                                                                                                                                                                                                                          None   \n",
       "5129                                                                                                                                                                                                                           None   \n",
       "50872                                                                                                                                                                   Explain the difference between prevention and inspection      \n",
       "34847                                                                                                                                              Describe the four types of software tests and explain how and why each is used     \n",
       "54156                                                                                                                                                                                                                          None   \n",
       "33285                                                                                                                                                                                                                          None   \n",
       "2943                                                                                                                                                                                                                           None   \n",
       "14260                                                                                                                                                                                                Publish your project online.     \n",
       "40629                                                                                                                                                                                                                          None   \n",
       "45862                                                                                                                                                            Understand the importance of Audience - Centric Communications       \n",
       "30895                                                                                                                                                                                                                                 \n",
       "8101                                                                                                                                                                                       Labor Policies and Wage Diffferentials     \n",
       "52013    Create strategies for addressing environmental, technical and organizational complexity when implementing program by t      ailoring    / applying advanced program management concepts to a program exercise/reflection     \n",
       "37060                                                                                                                                                                                                                          None   \n",
       "46600                                                                                                                                                  Confirm the theory you   wi  ll use as the foundation of your final project    \n",
       "48391                                                                                                                                                        Explain the importance of using best practices to initiate a project     \n",
       "13172                                                                                                                                                                                                                          None   \n",
       "23973                                                                                                                                                                                                                          None   \n",
       "23266                                                                                                                                                                                                                          None   \n",
       "898                                                                                                                                                                          Compare and contrast the PE Ratio with the PEG Ratio     \n",
       "57871                                                                                                                                                                                                                          None   \n",
       "4946                                                                                                                                                                                                practice experential learning     \n",
       "35240                                                                                                                                      ÔÇ∑ Create and configure virtual servers, adapters, and switches as part of a network.     \n",
       "43165                                                                                                                                                                                                                                 \n",
       "33920                                                                                                                                                                                                                                 \n",
       "52209                                                                                                              Create an understanding of how Agile projects must be integrated into the larger corporate project environment     \n",
       "26342                                                                                                                                                                           Define and calculate the marginal cost of capital.    \n",
       "33097                                                                                                                                                                                                                                 \n",
       "21265                                                                                                                                                                                                                                 \n",
       "40359                                                                                                                                                                                                                                 \n",
       "56131                                                                                                                                                                              Describe the Australian Medical device system      \n",
       "56032                                                                                                                                                 Obtain a working knowledge of the regulatory document hierarchy in the EU.      \n",
       "58315                                                                                                                                                                                               Parts of an oral presentation     \n",
       "58088                                                                                                                                                                                   Natural Substances                            \n",
       "55981         Understand that DTC broadcast advertisements are required to communicate the major statement of a drug's risk in a clear, conspicuous and neutral manner and review an OPDP draft regulation defining these terms.      \n",
       "22035                                                                                                                                                                                                                          None   \n",
       "30624                                                                                                                                                                                                                          None   \n",
       "33140                                                                                                                                                                                                                          None   \n",
       "38747                                                                                                                                                                                                                          None   \n",
       "3513                                                                                                                                        explain what  research  questions the authors are trying to answer with dashboards;       \n",
       "36283                                                                                                                                               Identify and explain the types of content that go into an EA Management Plan.     \n",
       "35044                                                                                                                                                                                      Create a Query with a Calculated Field     \n",
       "1385                                                                                                                                                                                                                           None   \n",
       "10594                                                                                                                                                     Several case studies relating to the principles of crisis communication     \n",
       "1119                                                                                                                                                                               Select the appropriate types of audit tests.       \n",
       "28946                                                                                                                                                                                                                          None   \n",
       "10999                                                                                                                                                       Work with a partner to provide feedback on each others' presentations     \n",
       "\n",
       "      los10  ... los780 los781 los782 los783 los784 los785 los786 los787  \\\n",
       "36386    |   ...   None   None   None   None   None   None   None   None   \n",
       "47873  None  ...   None   None   None   None   None   None   None   None   \n",
       "60       |   ...   None   None   None   None   None   None   None   None   \n",
       "36896  None  ...   None   None   None   None   None   None   None   None   \n",
       "34620    |   ...   None   None   None   None   None   None   None   None   \n",
       "6851     |   ...   None   None   None   None   None   None   None   None   \n",
       "48709    |   ...   None   None   None   None   None   None   None   None   \n",
       "1190   None  ...   None   None   None   None   None   None   None   None   \n",
       "21970  None  ...   None   None   None   None   None   None   None   None   \n",
       "5129   None  ...   None   None   None   None   None   None   None   None   \n",
       "50872    |   ...   None   None   None   None   None   None   None   None   \n",
       "34847    |   ...   None   None   None   None   None   None   None   None   \n",
       "54156  None  ...   None   None   None   None   None   None   None   None   \n",
       "33285  None  ...   None   None   None   None   None   None   None   None   \n",
       "2943   None  ...   None   None   None   None   None   None   None   None   \n",
       "14260    |   ...   None   None   None   None   None   None   None   None   \n",
       "40629  None  ...   None   None   None   None   None   None   None   None   \n",
       "45862    |   ...   None   None   None   None   None   None   None   None   \n",
       "30895  None  ...   None   None   None   None   None   None   None   None   \n",
       "8101     |   ...   None   None   None   None   None   None   None   None   \n",
       "52013    |   ...   None   None   None   None   None   None   None   None   \n",
       "37060  None  ...   None   None   None   None   None   None   None   None   \n",
       "46600    |   ...   None   None   None   None   None   None   None   None   \n",
       "48391    |   ...   None   None   None   None   None   None   None   None   \n",
       "13172  None  ...   None   None   None   None   None   None   None   None   \n",
       "23973  None  ...   None   None   None   None   None   None   None   None   \n",
       "23266  None  ...   None   None   None   None   None   None   None   None   \n",
       "898      |   ...   None   None   None   None   None   None   None   None   \n",
       "57871  None  ...   None   None   None   None   None   None   None   None   \n",
       "4946     |   ...   None   None   None   None   None   None   None   None   \n",
       "35240    |   ...   None   None   None   None   None   None   None   None   \n",
       "43165  None  ...   None   None   None   None   None   None   None   None   \n",
       "33920  None  ...   None   None   None   None   None   None   None   None   \n",
       "52209    |   ...   None   None   None   None   None   None   None   None   \n",
       "26342    |   ...   None   None   None   None   None   None   None   None   \n",
       "33097  None  ...   None   None   None   None   None   None   None   None   \n",
       "21265    |   ...   None   None   None   None   None   None   None   None   \n",
       "40359    |   ...   None   None   None   None   None   None   None   None   \n",
       "56131    |   ...   None   None   None   None   None   None   None   None   \n",
       "56032    |   ...   None   None   None   None   None   None   None   None   \n",
       "58315    |   ...   None   None   None   None   None   None   None   None   \n",
       "58088  None  ...   None   None   None   None   None   None   None   None   \n",
       "55981    |   ...   None   None   None   None   None   None   None   None   \n",
       "22035  None  ...   None   None   None   None   None   None   None   None   \n",
       "30624  None  ...   None   None   None   None   None   None   None   None   \n",
       "33140  None  ...   None   None   None   None   None   None   None   None   \n",
       "38747  None  ...   None   None   None   None   None   None   None   None   \n",
       "3513     |   ...   None   None   None   None   None   None   None   None   \n",
       "36283    |   ...   None   None   None   None   None   None   None   None   \n",
       "35044    |   ...   None   None   None   None   None   None   None   None   \n",
       "1385   None  ...   None   None   None   None   None   None   None   None   \n",
       "10594    |   ...   None   None   None   None   None   None   None   None   \n",
       "1119     |   ...   None   None   None   None   None   None   None   None   \n",
       "28946  None  ...   None   None   None   None   None   None   None   None   \n",
       "10999    |   ...   None   None   None   None   None   None   None   None   \n",
       "\n",
       "      los788 los789  \n",
       "36386   None   None  \n",
       "47873   None   None  \n",
       "60      None   None  \n",
       "36896   None   None  \n",
       "34620   None   None  \n",
       "6851    None   None  \n",
       "48709   None   None  \n",
       "1190    None   None  \n",
       "21970   None   None  \n",
       "5129    None   None  \n",
       "50872   None   None  \n",
       "34847   None   None  \n",
       "54156   None   None  \n",
       "33285   None   None  \n",
       "2943    None   None  \n",
       "14260   None   None  \n",
       "40629   None   None  \n",
       "45862   None   None  \n",
       "30895   None   None  \n",
       "8101    None   None  \n",
       "52013   None   None  \n",
       "37060   None   None  \n",
       "46600   None   None  \n",
       "48391   None   None  \n",
       "13172   None   None  \n",
       "23973   None   None  \n",
       "23266   None   None  \n",
       "898     None   None  \n",
       "57871   None   None  \n",
       "4946    None   None  \n",
       "35240   None   None  \n",
       "43165   None   None  \n",
       "33920   None   None  \n",
       "52209   None   None  \n",
       "26342   None   None  \n",
       "33097   None   None  \n",
       "21265   None   None  \n",
       "40359   None   None  \n",
       "56131   None   None  \n",
       "56032   None   None  \n",
       "58315   None   None  \n",
       "58088   None   None  \n",
       "55981   None   None  \n",
       "22035   None   None  \n",
       "30624   None   None  \n",
       "33140   None   None  \n",
       "38747   None   None  \n",
       "3513    None   None  \n",
       "36283   None   None  \n",
       "35044   None   None  \n",
       "1385    None   None  \n",
       "10594   None   None  \n",
       "1119    None   None  \n",
       "28946   None   None  \n",
       "10999   None   None  \n",
       "\n",
       "[55 rows x 789 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df2.sample(n=55)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://www.w3resource.com/pandas/series/series-reset_index.php\n",
    "#https://stackoverflow.com/questions/32801806/pandas-concat-ignore-index-doesnt-work\n",
    "df1.reset_index(drop=True, inplace=True)\n",
    "df2.reset_index(drop=True, inplace=True)\n",
    "\n",
    "df3 = pd.concat( [df1, df2], axis=1) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>title</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "      <th>los1</th>\n",
       "      <th>los2</th>\n",
       "      <th>los3</th>\n",
       "      <th>los4</th>\n",
       "      <th>los5</th>\n",
       "      <th>...</th>\n",
       "      <th>los780</th>\n",
       "      <th>los781</th>\n",
       "      <th>los782</th>\n",
       "      <th>los783</th>\n",
       "      <th>los784</th>\n",
       "      <th>los785</th>\n",
       "      <th>los786</th>\n",
       "      <th>los787</th>\n",
       "      <th>los788</th>\n",
       "      <th>los789</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>18599</th>\n",
       "      <td>EDU7210</td>\n",
       "      <td>Week 7: Leadership for Social Change</td>\n",
       "      <td>Learning Objectives:</td>\n",
       "      <td>\\n   \\n    Identify a social change process and consider likely action steps.   \\n    Compare and contrast differing  perspectives on the social change initiative.   \\n   \\n   \\n       \\n  \\n</td>\n",
       "      <td>|     |     Identify a social change process and consider likely action steps.    |     Compare and contrast differing  perspectives on the social change initiative.    |     |     |         |    |</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Identify a social change process and consider likely action steps.</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24355</th>\n",
       "      <td>ENG1105</td>\n",
       "      <td>Week 14: Podcasts and S-L Expo</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36124</th>\n",
       "      <td>ITC6000</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14517</th>\n",
       "      <td>DGM6501</td>\n",
       "      <td>Week 10: Final Project  Workshop</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to   \\n Practice presenting final project</td>\n",
       "      <td>By the end of the week, you will have the opportunity to    |  Practice presenting final project</td>\n",
       "      <td>By the end of the week, you will have the opportunity to</td>\n",
       "      <td>|</td>\n",
       "      <td>Practice presenting final project</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25795</th>\n",
       "      <td>ENG3300</td>\n",
       "      <td>Week 3: A Responsibility to Act</td>\n",
       "      <td>Learning Objectives</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:  \\r\\n \\r\\n Revise your draft based on the feedback you receive from me on your rough draft  \\r\\n Submit your final draft of your Unit 1 paper \\r\\n Read a critical essay about  The Secret Sharer  \\r\\n Participate in the week 3 discussion forum.  \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   |  |   |  |  Revise your draft based on the feedback you receive from me on your rough draft    |  |  Submit your final draft of your Unit 1 paper  |  |  Read a critical essay about   The Secret Sharer   |  |  Participate in the week 3 discussion forum.    |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td></td>\n",
       "      <td>|</td>\n",
       "      <td>Revise your draft based on the feedback you receive from me on your rough draft</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 794 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      course_id                                folder                 title  \\\n",
       "18599   EDU7210  Week 7: Leadership for Social Change  Learning Objectives:   \n",
       "24355   ENG1105        Week 14: Podcasts and S-L Expo   Learning Objectives   \n",
       "36124   ITC6000        Week 1: Name weekly topic here   Learning Objectives   \n",
       "14517   DGM6501      Week 10: Final Project  Workshop   Learning Objectives   \n",
       "25795   ENG3300       Week 3: A Responsibility to Act   Learning Objectives   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                    main_data  \\\n",
       "18599                                                                                                                      \\n   \\n    Identify a social change process and consider likely action steps.   \\n    Compare and contrast differing  perspectives on the social change initiative.   \\n   \\n   \\n       \\n  \\n      \n",
       "24355                                                                                                                                                                                                                                                          By the end of the week, you will have the opportunity to:        \n",
       "36124                                                                                                                                                                                                                                                          By the end of the week, you will have the opportunity to:        \n",
       "14517                                                                                                                                                                                                                        By the end of the week, you will have the opportunity to   \\n Practice presenting final project    \n",
       "25795    By the end of the week, you will have the opportunity to:  \\r\\n \\r\\n Revise your draft based on the feedback you receive from me on your rough draft  \\r\\n Submit your final draft of your Unit 1 paper \\r\\n Read a critical essay about  The Secret Sharer  \\r\\n Participate in the week 3 discussion forum.  \\r\\n    \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                 los  \\\n",
       "18599                                                                                                                              |     |     Identify a social change process and consider likely action steps.    |     Compare and contrast differing  perspectives on the social change initiative.    |     |     |         |    |                               \n",
       "24355                                                                                                                                                                                                                                                                         By the end of the week, you will have the opportunity to:                                \n",
       "36124                                                                                                                                                                                                                                                                         By the end of the week, you will have the opportunity to:                                \n",
       "14517                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to    |  Practice presenting final project                            \n",
       "25795    By the end of the week, you will have the opportunity to:   |  |   |  |  Revise your draft based on the feedback you receive from me on your rough draft    |  |  Submit your final draft of your Unit 1 paper  |  |  Read a critical essay about   The Secret Sharer   |  |  Participate in the week 3 discussion forum.    |  |                             \n",
       "\n",
       "                                                                                          los1  \\\n",
       "18599                                                                                            \n",
       "24355   By the end of the week, you will have the opportunity to:                                \n",
       "36124   By the end of the week, you will have the opportunity to:                                \n",
       "14517                              By the end of the week, you will have the opportunity to      \n",
       "25795                              By the end of the week, you will have the opportunity to:     \n",
       "\n",
       "       los2                                                         los3  \\\n",
       "18599    |                                                                 \n",
       "24355  None                                                         None   \n",
       "36124  None                                                         None   \n",
       "14517    |    Practice presenting final project                            \n",
       "25795    |                                                                 \n",
       "\n",
       "       los4  \\\n",
       "18599    |    \n",
       "24355  None   \n",
       "36124  None   \n",
       "14517  None   \n",
       "25795    |    \n",
       "\n",
       "                                                                                      los5  \\\n",
       "18599                Identify a social change process and consider likely action steps.      \n",
       "24355                                                                                 None   \n",
       "36124                                                                                 None   \n",
       "14517                                                                                 None   \n",
       "25795   Revise your draft based on the feedback you receive from me on your rough draft      \n",
       "\n",
       "       ... los780 los781 los782 los783 los784 los785 los786 los787 los788  \\\n",
       "18599  ...   None   None   None   None   None   None   None   None   None   \n",
       "24355  ...   None   None   None   None   None   None   None   None   None   \n",
       "36124  ...   None   None   None   None   None   None   None   None   None   \n",
       "14517  ...   None   None   None   None   None   None   None   None   None   \n",
       "25795  ...   None   None   None   None   None   None   None   None   None   \n",
       "\n",
       "      los789  \n",
       "18599   None  \n",
       "24355   None  \n",
       "36124   None  \n",
       "14517   None  \n",
       "25795   None  \n",
       "\n",
       "[5 rows x 794 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df3.sample(n=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "df3[\"title\"] = df3[\"title\"].str.lower()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "objectives    56521\n",
       "learning      55867\n",
       ".              1829\n",
       "and             692\n",
       "week            506\n",
       "              ...  \n",
       "03                1\n",
       "wk5:              1\n",
       "04                1\n",
       "lab               1\n",
       "topic             1\n",
       "Length: 325, dtype: int64"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df3.title.str.split(expand=True).stack().value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "df3.drop(['title'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://stackoverflow.com/questions/13445241/replacing-blank-values-white-space-with-nan-in-pandas\n",
    "df3.replace(r'^\\s*$', np.nan, regex=True, inplace = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "      <th>los1</th>\n",
       "      <th>los2</th>\n",
       "      <th>los3</th>\n",
       "      <th>los4</th>\n",
       "      <th>los5</th>\n",
       "      <th>los6</th>\n",
       "      <th>...</th>\n",
       "      <th>los780</th>\n",
       "      <th>los781</th>\n",
       "      <th>los782</th>\n",
       "      <th>los783</th>\n",
       "      <th>los784</th>\n",
       "      <th>los785</th>\n",
       "      <th>los786</th>\n",
       "      <th>los787</th>\n",
       "      <th>los788</th>\n",
       "      <th>los789</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>941</th>\n",
       "      <td>ACC4320</td>\n",
       "      <td>Week 2:  Asset and Liability Valuation and Income Recognition</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:   \\n  \\n \\n       Mixed Attribute Accounting Model  \\n  \\n \\n       To simplify the complexity of valuation of assets and liabilities in real companies.  \\n  \\n \\n       Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.  \\n  \\n \\n       Recommended by U.S. GAAP and IFRS.  \\n  \\n \\n       Asset and Liability Valuation  \\n  \\n \\n      FASB Statement No. 2 - Primary qualities of accounting information:  \\n  \\n \\n      Relevance  \\n  \\n \\n      Reliability     \\n  \\n \\n      Valuations of assets and liabilities reflect   \\n  \\n \\n      Historical data  \\n  \\n \\n      Current information  \\n  \\n \\n      Expectations of future outcomes  \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n      Mixed Attribute Accounting Model is used to  \\n  \\n \\n       Provide an optimal mix of   relevant   and   reliable   information in the financial statements.  \\n  \\n \\n       Help users better translate the information into   \\n  \\n \\n       Assessments of the risk   \\n  \\n \\n       Timing  \\n  \\n \\n       Amounts of future cash flows  \\n  \\n \\n       \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n       Historical Value  \\n  \\n \\n       Acquisition Cost  \\n  \\n \\n       Amount paid initially to acquire the asset.  \\n  \\n \\n       Includes all costs required to prepare the asset for its intended use.  \\n  \\n \\n       Examples: Sales tax, shipping, repair and maintenance  \\n  \\n \\n       Excludes costs to operate the asset.  \\n  \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Adjusted Acquisition Cost  \\n  \\n \\n       Service potential is consumed gradually or immediately.  \\n  \\n \\n       The asset is reduced and an expense is increased.  \\n  \\n \\n       Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.  \\n  \\n   \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Initial Present Value  \\n  \\n \\n       Monetary asset or liability.  \\n  \\n \\n       Present value computation uses appropriate interest rates .  \\n  \\n \\n       Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.  \\n  \\n \\n       Current Values  \\n  \\n \\n       Fair Value  \\n  \\n \\n       FASB - Exit Price; IASB - Exit or Entry Price   \\n  \\n \\n       Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7   \\n  \\n \\n       Examples:   \\n  \\n \\n       Investments in marketable equity and debt securities   \\n  \\n \\n       Financial instruments and derivative instruments   \\n  \\n \\n       Fair Value   \\n  \\n \\n       Income Recognition  \\n  \\n \\n       Recognition   ‚Üí   Making an entry to record a transaction or an event.  \\n  \\n \\n       In real world,  all changes in the economic value of a firm  are   not   reflected.  \\n  \\n \\n       Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.  \\n  \\n \\n      \\n  \\n \\n     \\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:    |    |   |        Mixed Attribute Accounting Model   |    |   |        To simplify the complexity of valuation of assets and liabilities in real companies.   |    |   |        Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.   |    |   |        Recommended by U.S. GAAP and IFRS.   |    |   |        Asset and Liability Valuation   |    |   |       FASB Statement No. 2 - Primary qualities of accounting information:   |    |   |       Relevance   |    |   |       Reliability      |    |   |       Valuations of assets and liabilities reflect    |    |   |       Historical data   |    |   |       Current information   |    |   |       Expectations of future outcomes   |    |   |        Asset and Liability Valuation (Contd.)   |    |   |       Mixed Attribute Accounting Model is used to   |    |   |        Provide an optimal mix of   relevant   and   reliable   information in the financial statements.   |    |   |        Help users better translate the information into    |    |   |        Assessments of the risk    |    |   |        Timing   |    |   |        Amounts of future cash flows   |    |   |         |    |   |        Asset and Liability Valuation (Contd.)   |    |   |        Historical Value   |    |   |        Acquisition Cost   |    |   |        Amount paid initially to acquire the asset.   |    |   |        Includes all costs required to prepare the asset for its intended use.   |    |   |        Examples: Sales tax, shipping, repair and maintenance   |    |   |        Excludes costs to operate the asset.   |    |   |        Historical Value (Contd.)   |    |   |        Adjusted Acquisition Cost   |    |   |        Service potential is consumed gradually or immediately.   |    |   |        The asset is reduced and an expense is increased.   |    |   |        Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.   |    |     |   |        Historical Value (Contd.)   |    |   |        Initial Present Value   |    |   |        Monetary asset or liability.   |    |   |        Present value computation uses appropriate interest rates .   |    |   |        Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.   |    |   |        Current Values   |    |   |        Fair Value   |    |   |        FASB - Exit Price; IASB - Exit or Entry Price    |    |   |        Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7    |    |   |        Examples:    |    |   |        Investments in marketable equity and debt securities    |    |   |        Financial instruments and derivative instruments    |    |   |        Fair Value    |    |   |        Income Recognition   |    |   |        Recognition   ‚Üí   Making an entry to record a transaction or an event.   |    |   |        In real world,  all changes in the economic value of a firm  are   not   reflected.   |    |   |        Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.   |    |   |        |    |   |       |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1033</th>\n",
       "      <td>ACC4320</td>\n",
       "      <td>Week 2:  Asset and Liability Valuation and Income Recognition</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:   \\n  \\n \\n       Mixed Attribute Accounting Model  \\n  \\n \\n       To simplify the complexity of valuation of assets and liabilities in real companies.  \\n  \\n \\n       Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.  \\n  \\n \\n       Recommended by U.S. GAAP and IFRS.  \\n  \\n \\n       Asset and Liability Valuation  \\n  \\n \\n      FASB Statement No. 2 - Primary qualities of accounting information:  \\n  \\n \\n      Relevance  \\n  \\n \\n      Reliability     \\n  \\n \\n      Valuations of assets and liabilities reflect   \\n  \\n \\n      Historical data  \\n  \\n \\n      Current information  \\n  \\n \\n      Expectations of future outcomes  \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n      Mixed Attribute Accounting Model is used to  \\n  \\n \\n       Provide an optimal mix of   relevant   and   reliable   information in the financial statements.  \\n  \\n \\n       Help users better translate the information into   \\n  \\n \\n       Assessments of the risk   \\n  \\n \\n       Timing  \\n  \\n \\n       Amounts of future cash flows  \\n  \\n \\n       \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n       Historical Value  \\n  \\n \\n       Acquisition Cost  \\n  \\n \\n       Amount paid initially to acquire the asset.  \\n  \\n \\n       Includes all costs required to prepare the asset for its intended use.  \\n  \\n \\n       Examples: Sales tax, shipping, repair and maintenance  \\n  \\n \\n       Excludes costs to operate the asset.  \\n  \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Adjusted Acquisition Cost  \\n  \\n \\n       Service potential is consumed gradually or immediately.  \\n  \\n \\n       The asset is reduced and an expense is increased.  \\n  \\n \\n       Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.  \\n  \\n   \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Initial Present Value  \\n  \\n \\n       Monetary asset or liability.  \\n  \\n \\n       Present value computation uses appropriate interest rates .  \\n  \\n \\n       Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.  \\n  \\n \\n       Current Values  \\n  \\n \\n       Fair Value  \\n  \\n \\n       FASB - Exit Price; IASB - Exit or Entry Price   \\n  \\n \\n       Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7   \\n  \\n \\n       Examples:   \\n  \\n \\n       Investments in marketable equity and debt securities   \\n  \\n \\n       Financial instruments and derivative instruments   \\n  \\n \\n       Fair Value   \\n  \\n \\n       Income Recognition  \\n  \\n \\n       Recognition   ‚Üí   Making an entry to record a transaction or an event.  \\n  \\n \\n       In real world,  all changes in the economic value of a firm  are   not   reflected.  \\n  \\n \\n       Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.  \\n  \\n \\n      \\n  \\n \\n     \\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:    |    |   |        Mixed Attribute Accounting Model   |    |   |        To simplify the complexity of valuation of assets and liabilities in real companies.   |    |   |        Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.   |    |   |        Recommended by U.S. GAAP and IFRS.   |    |   |        Asset and Liability Valuation   |    |   |       FASB Statement No. 2 - Primary qualities of accounting information:   |    |   |       Relevance   |    |   |       Reliability      |    |   |       Valuations of assets and liabilities reflect    |    |   |       Historical data   |    |   |       Current information   |    |   |       Expectations of future outcomes   |    |   |        Asset and Liability Valuation (Contd.)   |    |   |       Mixed Attribute Accounting Model is used to   |    |   |        Provide an optimal mix of   relevant   and   reliable   information in the financial statements.   |    |   |        Help users better translate the information into    |    |   |        Assessments of the risk    |    |   |        Timing   |    |   |        Amounts of future cash flows   |    |   |         |    |   |        Asset and Liability Valuation (Contd.)   |    |   |        Historical Value   |    |   |        Acquisition Cost   |    |   |        Amount paid initially to acquire the asset.   |    |   |        Includes all costs required to prepare the asset for its intended use.   |    |   |        Examples: Sales tax, shipping, repair and maintenance   |    |   |        Excludes costs to operate the asset.   |    |   |        Historical Value (Contd.)   |    |   |        Adjusted Acquisition Cost   |    |   |        Service potential is consumed gradually or immediately.   |    |   |        The asset is reduced and an expense is increased.   |    |   |        Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.   |    |     |   |        Historical Value (Contd.)   |    |   |        Initial Present Value   |    |   |        Monetary asset or liability.   |    |   |        Present value computation uses appropriate interest rates .   |    |   |        Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.   |    |   |        Current Values   |    |   |        Fair Value   |    |   |        FASB - Exit Price; IASB - Exit or Entry Price    |    |   |        Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7    |    |   |        Examples:    |    |   |        Investments in marketable equity and debt securities    |    |   |        Financial instruments and derivative instruments    |    |   |        Fair Value    |    |   |        Income Recognition   |    |   |        Recognition   ‚Üí   Making an entry to record a transaction or an event.   |    |   |        In real world,  all changes in the economic value of a firm  are   not   reflected.   |    |   |        Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.   |    |   |        |    |   |       |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to understand:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1172</th>\n",
       "      <td>ACC4420</td>\n",
       "      <td>Week 2</td>\n",
       "      <td>CHAPTER 3 LEARNING OBJECTIVES:    \\n  Consolidations - Subsequent to the Date of Acquisition     \\n    \\n  \\n   \\n    \\n     LO1   \\n    Recognize the complexities in preparing consolidated financial reports that emerge from the passage of time.  \\n    \\n    \\n     LO2   \\n    Identify and describe the various methods available to a parent company in order to maintain its investment in subsidiary account in its internal records.  \\n    \\n    \\n     LO3   \\n    Understand that a parent's internal accounting method for its subsidiary investments has no effect on the resulting consolidated financial statements.  \\n    \\n    \\n     LO4   \\n    Prepare consolidated financial statements subsequent to acquisition when the parent has applied in its internal records:\\n      \\n      The equity method.  \\n      The initial value method.  \\n      The partial equity method.  \\n       \\n    \\n    \\n     LO5   \\n    Discuss the rationale for the goodwill impairment testing approach.  \\n    \\n    \\n     LO6   \\n    Describe the procedures for conducting a goodwill impairment test.  \\n    \\n    \\n     LO7   \\n    Understand the accounting and reporting for contingent consideration subsequent to a business acquisition.  \\n    \\n    \\n     LO8   \\n    Understand in general the requirements of pushdown accounting and when its use is appropriate.  \\n    \\n   \\n  \\n    \\n   CHAPTER 4 LEARNING OBJECTIVES    \\n  Consolidated Financial Statements and Outside Ownership   \\n    \\n  \\n   \\n    \\n     LO1   \\n    Understand that complete ownership is not a prerequisite for the formation of a business combination.  \\n    \\n    \\n     LO2   \\n    Describe the valuation principles underlying the acquisition method of accounting for the noncontrolling interest.  \\n    \\n    \\n     LO3   \\n    Allocate goodwill acquired in a business combination across the controlling and noncontrolling interests.  \\n    \\n    \\n     LO4   \\n    Understand the computation and allocation of consolidated net income in the presence of a noncontrolling interest.  \\n    \\n    \\n     LO5   \\n    Identify and calculate the four noncontrolling interest figures that must be included within the consolidation process and prepare a consolidation worksheet in the presence of a noncontrolling interest.  \\n    \\n    \\n     LO6   \\n    Identify appropriate placements for the components of the noncontrolling interest in consolidated financial statements.  \\n    \\n    \\n     LO7   \\n    Determine the effect on consolidated financial statements of a control premium paid by the parent.  \\n    \\n    \\n     LO8   \\n    Understand the impact on consolidated financial statements of a midyear acquisition.  \\n    \\n    \\n     LO9   \\n    Understand the impact on consolidated financial statements when a step acquisition has taken place.  \\n    \\n    \\n     LO10   \\n    Record the sale of a subsidiary (or a portion of its shares).  \\n    \\n   \\n  \\n    \\n</td>\n",
       "      <td>CHAPTER 3 LEARNING OBJECTIVES:     |   Consolidations - Subsequent to the Date of Acquisition      |      |    |     |      |      LO1    |     Recognize the complexities in preparing consolidated financial reports that emerge from the passage of time.   |      |      |      LO2    |     Identify and describe the various methods available to a parent company in order to maintain its investment in subsidiary account in its internal records.   |      |      |      LO3    |     Understand that a parent's internal accounting method for its subsidiary investments has no effect on the resulting consolidated financial statements.   |      |      |      LO4    |     Prepare consolidated financial statements subsequent to acquisition when the parent has applied in its internal records: |        |       The equity method.   |       The initial value method.   |       The partial equity method.   |         |      |      |      LO5    |     Discuss the rationale for the goodwill impairment testing approach.   |      |      |      LO6    |     Describe the procedures for conducting a goodwill impairment test.   |      |      |      LO7    |     Understand the accounting and reporting for contingent consideration subsequent to a business acquisition.   |      |      |      LO8    |     Understand in general the requirements of pushdown accounting and when its use is appropriate.   |      |     |    |      |    CHAPTER 4 LEARNING OBJECTIVES     |   Consolidated Financial Statements and Outside Ownership    |      |    |     |      |      LO1    |     Understand that complete ownership is not a prerequisite for the formation of a business combination.   |      |      |      LO2    |     Describe the valuation principles underlying the acquisition method of accounting for the noncontrolling interest.   |      |      |      LO3    |     Allocate goodwill acquired in a business combination across the controlling and noncontrolling interests.   |      |      |      LO4    |     Understand the computation and allocation of consolidated net income in the presence of a noncontrolling interest.   |      |      |      LO5    |     Identify and calculate the four noncontrolling interest figures that must be included within the consolidation process and prepare a consolidation worksheet in the presence of a noncontrolling interest.   |      |      |      LO6    |     Identify appropriate placements for the components of the noncontrolling interest in consolidated financial statements.   |      |      |      LO7    |     Determine the effect on consolidated financial statements of a control premium paid by the parent.   |      |      |      LO8    |     Understand the impact on consolidated financial statements of a midyear acquisition.   |      |      |      LO9    |     Understand the impact on consolidated financial statements when a step acquisition has taken place.   |      |      |      LO10    |     Record the sale of a subsidiary (or a portion of its shares).   |      |     |    |      |</td>\n",
       "      <td>CHAPTER 3 LEARNING OBJECTIVES:</td>\n",
       "      <td>|</td>\n",
       "      <td>Consolidations - Subsequent to the Date of Acquisition</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1174</th>\n",
       "      <td>ACC4420</td>\n",
       "      <td>Week 4</td>\n",
       "      <td>CHAPTER 7 LEARNING OBJECTIVES:    \\n  Consolidated Financial Statements - Ownership Patterns and Income Taxes   \\n  \\n   \\n    \\n     LO1   \\n    Understand the implications for the consolidation process when indirect control is present in a grandfather-father-son ownership configuration.  \\n    \\n    \\n     LO2   \\n    Understand the implications for the consolidation process when a corporate ownership structure is characterized by a connecting affiliation.  \\n    \\n    \\n     LO3   \\n    Understand the implications for the consolidation process when a corporate ownership structure is characterized by mutual ownership.  \\n    \\n    \\n     LO4   \\n      List the criteria for being a member of an affiliated group for income tax filing purposes.    \\n    \\n    \\n     LO5   \\n      Compute taxable income and deferred tax amounts for an affiliated group based on information presented in a consolidated set of financial statements.    \\n    \\n    \\n     LO6   \\n      Compute taxable income and deferred tax amounts to be recognized when separate tax returns are filed by any of the affiliates of a business combination.    \\n    \\n    \\n     LO7   \\n      Determine the deferred tax consequences for temporary differences generated when a business combination is created.    \\n    \\n    \\n     LO8   \\n      Explain the impact that a net operating loss of an acquired affiliate has on consolidated figures.    \\n    \\n   \\n  \\n     \\n     \\n  CHAPTER 8 LEARNING OBJECTIVES:   \\n  Segment and Interim Reporting   \\n  \\n   \\n    \\n     LO1   \\n      Understand how an enterprise determines its operating segments and the factors that influence this determination.    \\n    \\n    \\n     LO2   \\n      Apply the three tests that are used to determine which operating segments are of significant size to warrant separate disclosure.    \\n    \\n    \\n     LO3   \\n    List the basic disclosure requirements for operating segments.  \\n    \\n    \\n     LO4   \\n      Determine when and what types of information must be disclosed for geographic areas.    \\n    \\n    \\n     LO5   \\n      Apply the criterion for determining when disclosure of a major customer is required.    \\n    \\n    \\n     LO6   \\n      Recognize differences between U.S. GAAP and IFRS in segment reporting.    \\n    \\n    \\n     LO7   \\n      Understand and apply procedures used in interim reports to treat an interim period as an integral part of the annual period.    \\n    \\n    \\n     LO8   \\n      List the minimum disclosure requirements for interim financial reports.    \\n    \\n    \\n     LO9   \\n      Recognize differences between U.S. GAAP and IFRS in interim reporting    \\n    \\n   \\n  \\n</td>\n",
       "      <td>CHAPTER 7 LEARNING OBJECTIVES:     |   Consolidated Financial Statements - Ownership Patterns and Income Taxes    |    |     |      |      LO1    |     Understand the implications for the consolidation process when indirect control is present in a grandfather-father-son ownership configuration.   |      |      |      LO2    |     Understand the implications for the consolidation process when a corporate ownership structure is characterized by a connecting affiliation.   |      |      |      LO3    |     Understand the implications for the consolidation process when a corporate ownership structure is characterized by mutual ownership.   |      |      |      LO4    |       List the criteria for being a member of an affiliated group for income tax filing purposes.     |      |      |      LO5    |       Compute taxable income and deferred tax amounts for an affiliated group based on information presented in a consolidated set of financial statements.     |      |      |      LO6    |       Compute taxable income and deferred tax amounts to be recognized when separate tax returns are filed by any of the affiliates of a business combination.     |      |      |      LO7    |       Determine the deferred tax consequences for temporary differences generated when a business combination is created.     |      |      |      LO8    |       Explain the impact that a net operating loss of an acquired affiliate has on consolidated figures.     |      |     |    |       |       |   CHAPTER 8 LEARNING OBJECTIVES:    |   Segment and Interim Reporting    |    |     |      |      LO1    |       Understand how an enterprise determines its operating segments and the factors that influence this determination.     |      |      |      LO2    |       Apply the three tests that are used to determine which operating segments are of significant size to warrant separate disclosure.     |      |      |      LO3    |     List the basic disclosure requirements for operating segments.   |      |      |      LO4    |       Determine when and what types of information must be disclosed for geographic areas.     |      |      |      LO5    |       Apply the criterion for determining when disclosure of a major customer is required.     |      |      |      LO6    |       Recognize differences between U.S. GAAP and IFRS in segment reporting.     |      |      |      LO7    |       Understand and apply procedures used in interim reports to treat an interim period as an integral part of the annual period.     |      |      |      LO8    |       List the minimum disclosure requirements for interim financial reports.     |      |      |      LO9    |       Recognize differences between U.S. GAAP and IFRS in interim reporting     |      |     |    |</td>\n",
       "      <td>CHAPTER 7 LEARNING OBJECTIVES:</td>\n",
       "      <td>|</td>\n",
       "      <td>Consolidated Financial Statements - Ownership Patterns and Income Taxes</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1177</th>\n",
       "      <td>ACC4420</td>\n",
       "      <td>Week 7</td>\n",
       "      <td>CHAPTER 16 LEARNING OBJECTIVES:    \\n   \\n  \\n   \\n    \\n     LO 16-1   \\n    Explain the history of and the reasons for the unique characteristics of the financial statements produced by state and local governments.  \\n    \\n    \\n     LO 16-2   \\n    Differentiate between the two sets of financial statements produced by state and local governments.  \\n    \\n    \\n     LO 16-3   \\n    Understand the reason that fund accounting has traditionally been a prominent factor in the internal recording of state and local governments.  \\n    \\n    \\n     LO 16-4   \\n    Identify the three fund types and the individual fund categories within each.  \\n    \\n    \\n     LO 16-5   \\n    Understand the basic structure of government-wide financial statements and fund financial statements (as produced for the governmental funds).  \\n    \\n    \\n     LO 16-6   \\n    Record the passage of a budget as well as subsequent encumbrances and expenditures.  \\n    \\n    \\n     LO 16-7   \\n    Understand the reporting of capital assets, supplies, and prepaid expenses by a state or local government.  \\n    \\n    \\n     LO 16-8   \\n    Determine the proper timing for the recognition of revenues from various types of nonexchange transactions.  \\n    \\n    \\n     LO 16-9   \\n    Account for the issuance of long-term bonds and the reporting of special assessment projects.  \\n    \\n    \\n     LO 16-10   \\n    Record the various types of monetary transfers that occur within the funds maintained by a state or local government.  \\n    \\n   \\n  \\n    \\n    \\n  CHAPTER 17 LEARNING OBJECTIVES:   \\n  \\n   \\n    \\n     LO 17-1   \\n    Account for lease contracts where the state or local government finds itself as either lessor or lessee.  \\n    \\n    \\n     LO 17-2   \\n    Recognize the liability caused by the eventual closure and postclosure costs of operating a solid waste landfill.  \\n    \\n    \\n     LO 17-3   \\n    Explain the reporting of a net pension liability resulting from a defined benefit pension plan provided to employees by a state or local government.  \\n    \\n    \\n     LO 17-4   \\n    Record the donation and acquisition of works of art and historical treasures.  \\n    \\n    \\n     LO 17-5   \\n    Explain the reporting and possible depreciation of infrastructure assets.  \\n    \\n    \\n     LO 17-6   \\n    Understand the composition of a state or local government's comprehensive annual financial report (CAFR).  \\n    \\n    \\n     LO 17-7   \\n    Explain the makeup of a primary government and its relationship to component units and related organizations as well as the combination of governments.  \\n    \\n    \\n     LO 17-8   \\n    Describe the physical structure of a complete set of government-wide financial statements and a complete set of fund financial statements.  \\n    \\n    \\n     LO 17-9   \\n    Understand the presentation of financial statements for a public college or university.  \\n    \\n   \\n</td>\n",
       "      <td>CHAPTER 16 LEARNING OBJECTIVES:     |     |    |     |      |      LO 16-1    |     Explain the history of and the reasons for the unique characteristics of the financial statements produced by state and local governments.   |      |      |      LO 16-2    |     Differentiate between the two sets of financial statements produced by state and local governments.   |      |      |      LO 16-3    |     Understand the reason that fund accounting has traditionally been a prominent factor in the internal recording of state and local governments.   |      |      |      LO 16-4    |     Identify the three fund types and the individual fund categories within each.   |      |      |      LO 16-5    |     Understand the basic structure of government-wide financial statements and fund financial statements (as produced for the governmental funds).   |      |      |      LO 16-6    |     Record the passage of a budget as well as subsequent encumbrances and expenditures.   |      |      |      LO 16-7    |     Understand the reporting of capital assets, supplies, and prepaid expenses by a state or local government.   |      |      |      LO 16-8    |     Determine the proper timing for the recognition of revenues from various types of nonexchange transactions.   |      |      |      LO 16-9    |     Account for the issuance of long-term bonds and the reporting of special assessment projects.   |      |      |      LO 16-10    |     Record the various types of monetary transfers that occur within the funds maintained by a state or local government.   |      |     |    |      |      |   CHAPTER 17 LEARNING OBJECTIVES:    |    |     |      |      LO 17-1    |     Account for lease contracts where the state or local government finds itself as either lessor or lessee.   |      |      |      LO 17-2    |     Recognize the liability caused by the eventual closure and postclosure costs of operating a solid waste landfill.   |      |      |      LO 17-3    |     Explain the reporting of a net pension liability resulting from a defined benefit pension plan provided to employees by a state or local government.   |      |      |      LO 17-4    |     Record the donation and acquisition of works of art and historical treasures.   |      |      |      LO 17-5    |     Explain the reporting and possible depreciation of infrastructure assets.   |      |      |      LO 17-6    |     Understand the composition of a state or local government's comprehensive annual financial report (CAFR).   |      |      |      LO 17-7    |     Explain the makeup of a primary government and its relationship to component units and related organizations as well as the combination of governments.   |      |      |      LO 17-8    |     Describe the physical structure of a complete set of government-wide financial statements and a complete set of fund financial statements.   |      |      |      LO 17-9    |     Understand the presentation of financial statements for a public college or university.   |      |     |</td>\n",
       "      <td>CHAPTER 16 LEARNING OBJECTIVES:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53814</th>\n",
       "      <td>PTH6110</td>\n",
       "      <td>Module 2: Neuroimaging, Cadiopulmonary imaging and Pediatrics</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:   \\r\\n  \\r\\n   \\r\\n  \\r\\n  \\r\\n\\r\\n Identify findings specific to normal and\\r\\npathological pediatric radiographs. \\r\\n\\r\\n Identify and select appropriate\\r\\nmodalities for neuro-imaging.  \\r\\n\\r\\n Use a systematic approach viewing\\r\\nneuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary\\r\\npathology viewed on radiographs.\\r\\n\\r\\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n   \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin-top:0in;\\r\\n\\tmso-para-margin-right:0in;\\r\\n\\tmso-para-margin-bottom:10.0pt;\\r\\n\\tmso-para-margin-left:0in;\\r\\n\\tline-height:115%;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:11.0pt;\\r\\n\\tfont-family:\"Calibri\",\"sans-serif\";\\r\\n\\tmso-ascii-font-family:Calibri;\\r\\n\\tmso-ascii-theme-font:minor-latin;\\r\\n\\tmso-hansi-font-family:Calibri;\\r\\n\\tmso-hansi-theme-font:minor-latin;}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:    |  |    |  |     |  |    |  |    |  |  |  |  Identify findings specific to normal and |  | pathological pediatric radiographs.  |  |  |  |  Identify and select appropriate |  | modalities for neuro-imaging.   |  |  |  |  Use a systematic approach viewing |  | neuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary |  | pathology viewed on radiographs. |  |  |  |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |     |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin-top:0in; |  |  | mso-para-margin-right:0in; |  |  | mso-para-margin-bottom:10.0pt; |  |  | mso-para-margin-left:0in; |  |  | line-height:115%; |  |  | mso-pagination:widow-orphan; |  |  | font-size:11.0pt; |  |  | font-family:\"Calibri\",\"sans-serif\"; |  |  | mso-ascii-font-family:Calibri; |  |  | mso-ascii-theme-font:minor-latin; |  |  | mso-hansi-font-family:Calibri; |  |  | mso-hansi-theme-font:minor-latin;} |  |   |  |</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56122</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>\"</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56134</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56182</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 11: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>\"</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56207</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>201 rows × 793 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      course_id  \\\n",
       "941     ACC4320   \n",
       "1033    ACC4320   \n",
       "1172    ACC4420   \n",
       "1174    ACC4420   \n",
       "1177    ACC4420   \n",
       "...         ...   \n",
       "53814   PTH6110   \n",
       "56122   RGA6223   \n",
       "56134   RGA6223   \n",
       "56182   RGA6223   \n",
       "56207   RGA6223   \n",
       "\n",
       "                                                                         folder  \\\n",
       "941               Week 2:  Asset and Liability Valuation and Income Recognition   \n",
       "1033              Week 2:  Asset and Liability Valuation and Income Recognition   \n",
       "1172                                                                     Week 2   \n",
       "1174                                                                     Week 4   \n",
       "1177                                                                     Week 7   \n",
       "...                                                                         ...   \n",
       "53814             Module 2: Neuroimaging, Cadiopulmonary imaging and Pediatrics   \n",
       "56122  Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56134  Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56182  Week 11: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56207  Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 main_data  \\\n",
       "941                                                                                                                                                                                                           By the end of the week, you will have the opportunity to understand:   \\n  \\n \\n       Mixed Attribute Accounting Model  \\n  \\n \\n       To simplify the complexity of valuation of assets and liabilities in real companies.  \\n  \\n \\n       Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.  \\n  \\n \\n       Recommended by U.S. GAAP and IFRS.  \\n  \\n \\n       Asset and Liability Valuation  \\n  \\n \\n      FASB Statement No. 2 - Primary qualities of accounting information:  \\n  \\n \\n      Relevance  \\n  \\n \\n      Reliability     \\n  \\n \\n      Valuations of assets and liabilities reflect   \\n  \\n \\n      Historical data  \\n  \\n \\n      Current information  \\n  \\n \\n      Expectations of future outcomes  \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n      Mixed Attribute Accounting Model is used to  \\n  \\n \\n       Provide an optimal mix of   relevant   and   reliable   information in the financial statements.  \\n  \\n \\n       Help users better translate the information into   \\n  \\n \\n       Assessments of the risk   \\n  \\n \\n       Timing  \\n  \\n \\n       Amounts of future cash flows  \\n  \\n \\n       \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n       Historical Value  \\n  \\n \\n       Acquisition Cost  \\n  \\n \\n       Amount paid initially to acquire the asset.  \\n  \\n \\n       Includes all costs required to prepare the asset for its intended use.  \\n  \\n \\n       Examples: Sales tax, shipping, repair and maintenance  \\n  \\n \\n       Excludes costs to operate the asset.  \\n  \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Adjusted Acquisition Cost  \\n  \\n \\n       Service potential is consumed gradually or immediately.  \\n  \\n \\n       The asset is reduced and an expense is increased.  \\n  \\n \\n       Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.  \\n  \\n   \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Initial Present Value  \\n  \\n \\n       Monetary asset or liability.  \\n  \\n \\n       Present value computation uses appropriate interest rates .  \\n  \\n \\n       Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.  \\n  \\n \\n       Current Values  \\n  \\n \\n       Fair Value  \\n  \\n \\n       FASB - Exit Price; IASB - Exit or Entry Price   \\n  \\n \\n       Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7   \\n  \\n \\n       Examples:   \\n  \\n \\n       Investments in marketable equity and debt securities   \\n  \\n \\n       Financial instruments and derivative instruments   \\n  \\n \\n       Fair Value   \\n  \\n \\n       Income Recognition  \\n  \\n \\n       Recognition   ‚Üí   Making an entry to record a transaction or an event.  \\n  \\n \\n       In real world,  all changes in the economic value of a firm  are   not   reflected.  \\n  \\n \\n       Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.  \\n  \\n \\n      \\n  \\n \\n     \\n    \n",
       "1033                                                                                                                                                                                                          By the end of the week, you will have the opportunity to understand:   \\n  \\n \\n       Mixed Attribute Accounting Model  \\n  \\n \\n       To simplify the complexity of valuation of assets and liabilities in real companies.  \\n  \\n \\n       Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.  \\n  \\n \\n       Recommended by U.S. GAAP and IFRS.  \\n  \\n \\n       Asset and Liability Valuation  \\n  \\n \\n      FASB Statement No. 2 - Primary qualities of accounting information:  \\n  \\n \\n      Relevance  \\n  \\n \\n      Reliability     \\n  \\n \\n      Valuations of assets and liabilities reflect   \\n  \\n \\n      Historical data  \\n  \\n \\n      Current information  \\n  \\n \\n      Expectations of future outcomes  \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n      Mixed Attribute Accounting Model is used to  \\n  \\n \\n       Provide an optimal mix of   relevant   and   reliable   information in the financial statements.  \\n  \\n \\n       Help users better translate the information into   \\n  \\n \\n       Assessments of the risk   \\n  \\n \\n       Timing  \\n  \\n \\n       Amounts of future cash flows  \\n  \\n \\n       \\n  \\n \\n       Asset and Liability Valuation (Contd.)  \\n  \\n \\n       Historical Value  \\n  \\n \\n       Acquisition Cost  \\n  \\n \\n       Amount paid initially to acquire the asset.  \\n  \\n \\n       Includes all costs required to prepare the asset for its intended use.  \\n  \\n \\n       Examples: Sales tax, shipping, repair and maintenance  \\n  \\n \\n       Excludes costs to operate the asset.  \\n  \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Adjusted Acquisition Cost  \\n  \\n \\n       Service potential is consumed gradually or immediately.  \\n  \\n \\n       The asset is reduced and an expense is increased.  \\n  \\n \\n       Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.  \\n  \\n   \\n \\n       Historical Value (Contd.)  \\n  \\n \\n       Initial Present Value  \\n  \\n \\n       Monetary asset or liability.  \\n  \\n \\n       Present value computation uses appropriate interest rates .  \\n  \\n \\n       Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.  \\n  \\n \\n       Current Values  \\n  \\n \\n       Fair Value  \\n  \\n \\n       FASB - Exit Price; IASB - Exit or Entry Price   \\n  \\n \\n       Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7   \\n  \\n \\n       Examples:   \\n  \\n \\n       Investments in marketable equity and debt securities   \\n  \\n \\n       Financial instruments and derivative instruments   \\n  \\n \\n       Fair Value   \\n  \\n \\n       Income Recognition  \\n  \\n \\n       Recognition   ‚Üí   Making an entry to record a transaction or an event.  \\n  \\n \\n       In real world,  all changes in the economic value of a firm  are   not   reflected.  \\n  \\n \\n       Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.  \\n  \\n \\n      \\n  \\n \\n     \\n    \n",
       "1172                                                                                                                                                                                                                                                                                                                                                                                                                                                                  CHAPTER 3 LEARNING OBJECTIVES:    \\n  Consolidations - Subsequent to the Date of Acquisition     \\n    \\n  \\n   \\n    \\n     LO1   \\n    Recognize the complexities in preparing consolidated financial reports that emerge from the passage of time.  \\n    \\n    \\n     LO2   \\n    Identify and describe the various methods available to a parent company in order to maintain its investment in subsidiary account in its internal records.  \\n    \\n    \\n     LO3   \\n    Understand that a parent's internal accounting method for its subsidiary investments has no effect on the resulting consolidated financial statements.  \\n    \\n    \\n     LO4   \\n    Prepare consolidated financial statements subsequent to acquisition when the parent has applied in its internal records:\\n      \\n      The equity method.  \\n      The initial value method.  \\n      The partial equity method.  \\n       \\n    \\n    \\n     LO5   \\n    Discuss the rationale for the goodwill impairment testing approach.  \\n    \\n    \\n     LO6   \\n    Describe the procedures for conducting a goodwill impairment test.  \\n    \\n    \\n     LO7   \\n    Understand the accounting and reporting for contingent consideration subsequent to a business acquisition.  \\n    \\n    \\n     LO8   \\n    Understand in general the requirements of pushdown accounting and when its use is appropriate.  \\n    \\n   \\n  \\n    \\n   CHAPTER 4 LEARNING OBJECTIVES    \\n  Consolidated Financial Statements and Outside Ownership   \\n    \\n  \\n   \\n    \\n     LO1   \\n    Understand that complete ownership is not a prerequisite for the formation of a business combination.  \\n    \\n    \\n     LO2   \\n    Describe the valuation principles underlying the acquisition method of accounting for the noncontrolling interest.  \\n    \\n    \\n     LO3   \\n    Allocate goodwill acquired in a business combination across the controlling and noncontrolling interests.  \\n    \\n    \\n     LO4   \\n    Understand the computation and allocation of consolidated net income in the presence of a noncontrolling interest.  \\n    \\n    \\n     LO5   \\n    Identify and calculate the four noncontrolling interest figures that must be included within the consolidation process and prepare a consolidation worksheet in the presence of a noncontrolling interest.  \\n    \\n    \\n     LO6   \\n    Identify appropriate placements for the components of the noncontrolling interest in consolidated financial statements.  \\n    \\n    \\n     LO7   \\n    Determine the effect on consolidated financial statements of a control premium paid by the parent.  \\n    \\n    \\n     LO8   \\n    Understand the impact on consolidated financial statements of a midyear acquisition.  \\n    \\n    \\n     LO9   \\n    Understand the impact on consolidated financial statements when a step acquisition has taken place.  \\n    \\n    \\n     LO10   \\n    Record the sale of a subsidiary (or a portion of its shares).  \\n    \\n   \\n  \\n    \\n     \n",
       "1174                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CHAPTER 7 LEARNING OBJECTIVES:    \\n  Consolidated Financial Statements - Ownership Patterns and Income Taxes   \\n  \\n   \\n    \\n     LO1   \\n    Understand the implications for the consolidation process when indirect control is present in a grandfather-father-son ownership configuration.  \\n    \\n    \\n     LO2   \\n    Understand the implications for the consolidation process when a corporate ownership structure is characterized by a connecting affiliation.  \\n    \\n    \\n     LO3   \\n    Understand the implications for the consolidation process when a corporate ownership structure is characterized by mutual ownership.  \\n    \\n    \\n     LO4   \\n      List the criteria for being a member of an affiliated group for income tax filing purposes.    \\n    \\n    \\n     LO5   \\n      Compute taxable income and deferred tax amounts for an affiliated group based on information presented in a consolidated set of financial statements.    \\n    \\n    \\n     LO6   \\n      Compute taxable income and deferred tax amounts to be recognized when separate tax returns are filed by any of the affiliates of a business combination.    \\n    \\n    \\n     LO7   \\n      Determine the deferred tax consequences for temporary differences generated when a business combination is created.    \\n    \\n    \\n     LO8   \\n      Explain the impact that a net operating loss of an acquired affiliate has on consolidated figures.    \\n    \\n   \\n  \\n     \\n     \\n  CHAPTER 8 LEARNING OBJECTIVES:   \\n  Segment and Interim Reporting   \\n  \\n   \\n    \\n     LO1   \\n      Understand how an enterprise determines its operating segments and the factors that influence this determination.    \\n    \\n    \\n     LO2   \\n      Apply the three tests that are used to determine which operating segments are of significant size to warrant separate disclosure.    \\n    \\n    \\n     LO3   \\n    List the basic disclosure requirements for operating segments.  \\n    \\n    \\n     LO4   \\n      Determine when and what types of information must be disclosed for geographic areas.    \\n    \\n    \\n     LO5   \\n      Apply the criterion for determining when disclosure of a major customer is required.    \\n    \\n    \\n     LO6   \\n      Recognize differences between U.S. GAAP and IFRS in segment reporting.    \\n    \\n    \\n     LO7   \\n      Understand and apply procedures used in interim reports to treat an interim period as an integral part of the annual period.    \\n    \\n    \\n     LO8   \\n      List the minimum disclosure requirements for interim financial reports.    \\n    \\n    \\n     LO9   \\n      Recognize differences between U.S. GAAP and IFRS in interim reporting    \\n    \\n   \\n  \\n       \n",
       "1177                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CHAPTER 16 LEARNING OBJECTIVES:    \\n   \\n  \\n   \\n    \\n     LO 16-1   \\n    Explain the history of and the reasons for the unique characteristics of the financial statements produced by state and local governments.  \\n    \\n    \\n     LO 16-2   \\n    Differentiate between the two sets of financial statements produced by state and local governments.  \\n    \\n    \\n     LO 16-3   \\n    Understand the reason that fund accounting has traditionally been a prominent factor in the internal recording of state and local governments.  \\n    \\n    \\n     LO 16-4   \\n    Identify the three fund types and the individual fund categories within each.  \\n    \\n    \\n     LO 16-5   \\n    Understand the basic structure of government-wide financial statements and fund financial statements (as produced for the governmental funds).  \\n    \\n    \\n     LO 16-6   \\n    Record the passage of a budget as well as subsequent encumbrances and expenditures.  \\n    \\n    \\n     LO 16-7   \\n    Understand the reporting of capital assets, supplies, and prepaid expenses by a state or local government.  \\n    \\n    \\n     LO 16-8   \\n    Determine the proper timing for the recognition of revenues from various types of nonexchange transactions.  \\n    \\n    \\n     LO 16-9   \\n    Account for the issuance of long-term bonds and the reporting of special assessment projects.  \\n    \\n    \\n     LO 16-10   \\n    Record the various types of monetary transfers that occur within the funds maintained by a state or local government.  \\n    \\n   \\n  \\n    \\n    \\n  CHAPTER 17 LEARNING OBJECTIVES:   \\n  \\n   \\n    \\n     LO 17-1   \\n    Account for lease contracts where the state or local government finds itself as either lessor or lessee.  \\n    \\n    \\n     LO 17-2   \\n    Recognize the liability caused by the eventual closure and postclosure costs of operating a solid waste landfill.  \\n    \\n    \\n     LO 17-3   \\n    Explain the reporting of a net pension liability resulting from a defined benefit pension plan provided to employees by a state or local government.  \\n    \\n    \\n     LO 17-4   \\n    Record the donation and acquisition of works of art and historical treasures.  \\n    \\n    \\n     LO 17-5   \\n    Explain the reporting and possible depreciation of infrastructure assets.  \\n    \\n    \\n     LO 17-6   \\n    Understand the composition of a state or local government's comprehensive annual financial report (CAFR).  \\n    \\n    \\n     LO 17-7   \\n    Explain the makeup of a primary government and its relationship to component units and related organizations as well as the combination of governments.  \\n    \\n    \\n     LO 17-8   \\n    Describe the physical structure of a complete set of government-wide financial statements and a complete set of fund financial statements.  \\n    \\n    \\n     LO 17-9   \\n    Understand the presentation of financial statements for a public college or university.  \\n    \\n   \\n    \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
       "53814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of this module, you will have the opportunity to:   \\r\\n  \\r\\n   \\r\\n  \\r\\n  \\r\\n\\r\\n Identify findings specific to normal and\\r\\npathological pediatric radiographs. \\r\\n\\r\\n Identify and select appropriate\\r\\nmodalities for neuro-imaging.  \\r\\n\\r\\n Use a systematic approach viewing\\r\\nneuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary\\r\\npathology viewed on radiographs.\\r\\n\\r\\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n   \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin-top:0in;\\r\\n\\tmso-para-margin-right:0in;\\r\\n\\tmso-para-margin-bottom:10.0pt;\\r\\n\\tmso-para-margin-left:0in;\\r\\n\\tline-height:115%;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:11.0pt;\\r\\n\\tfont-family:\"Calibri\",\"sans-serif\";\\r\\n\\tmso-ascii-font-family:Calibri;\\r\\n\\tmso-ascii-theme-font:minor-latin;\\r\\n\\tmso-hansi-font-family:Calibri;\\r\\n\\tmso-hansi-theme-font:minor-latin;}\\r\\n \\r\\n     \n",
       "56122   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56134   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56182   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56207   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      los  \\\n",
       "941                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of the week, you will have the opportunity to understand:    |    |   |        Mixed Attribute Accounting Model   |    |   |        To simplify the complexity of valuation of assets and liabilities in real companies.   |    |   |        Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.   |    |   |        Recommended by U.S. GAAP and IFRS.   |    |   |        Asset and Liability Valuation   |    |   |       FASB Statement No. 2 - Primary qualities of accounting information:   |    |   |       Relevance   |    |   |       Reliability      |    |   |       Valuations of assets and liabilities reflect    |    |   |       Historical data   |    |   |       Current information   |    |   |       Expectations of future outcomes   |    |   |        Asset and Liability Valuation (Contd.)   |    |   |       Mixed Attribute Accounting Model is used to   |    |   |        Provide an optimal mix of   relevant   and   reliable   information in the financial statements.   |    |   |        Help users better translate the information into    |    |   |        Assessments of the risk    |    |   |        Timing   |    |   |        Amounts of future cash flows   |    |   |         |    |   |        Asset and Liability Valuation (Contd.)   |    |   |        Historical Value   |    |   |        Acquisition Cost   |    |   |        Amount paid initially to acquire the asset.   |    |   |        Includes all costs required to prepare the asset for its intended use.   |    |   |        Examples: Sales tax, shipping, repair and maintenance   |    |   |        Excludes costs to operate the asset.   |    |   |        Historical Value (Contd.)   |    |   |        Adjusted Acquisition Cost   |    |   |        Service potential is consumed gradually or immediately.   |    |   |        The asset is reduced and an expense is increased.   |    |   |        Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.   |    |     |   |        Historical Value (Contd.)   |    |   |        Initial Present Value   |    |   |        Monetary asset or liability.   |    |   |        Present value computation uses appropriate interest rates .   |    |   |        Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.   |    |   |        Current Values   |    |   |        Fair Value   |    |   |        FASB - Exit Price; IASB - Exit or Entry Price    |    |   |        Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7    |    |   |        Examples:    |    |   |        Investments in marketable equity and debt securities    |    |   |        Financial instruments and derivative instruments    |    |   |        Fair Value    |    |   |        Income Recognition   |    |   |        Recognition   ‚Üí   Making an entry to record a transaction or an event.   |    |   |        In real world,  all changes in the economic value of a firm  are   not   reflected.   |    |   |        Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.   |    |   |        |    |   |       |                             \n",
       "1033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      By the end of the week, you will have the opportunity to understand:    |    |   |        Mixed Attribute Accounting Model   |    |   |        To simplify the complexity of valuation of assets and liabilities in real companies.   |    |   |        Proposes application of a standardized framework to analyze the impact of events and transactions on the financial statements.   |    |   |        Recommended by U.S. GAAP and IFRS.   |    |   |        Asset and Liability Valuation   |    |   |       FASB Statement No. 2 - Primary qualities of accounting information:   |    |   |       Relevance   |    |   |       Reliability      |    |   |       Valuations of assets and liabilities reflect    |    |   |       Historical data   |    |   |       Current information   |    |   |       Expectations of future outcomes   |    |   |        Asset and Liability Valuation (Contd.)   |    |   |       Mixed Attribute Accounting Model is used to   |    |   |        Provide an optimal mix of   relevant   and   reliable   information in the financial statements.   |    |   |        Help users better translate the information into    |    |   |        Assessments of the risk    |    |   |        Timing   |    |   |        Amounts of future cash flows   |    |   |         |    |   |        Asset and Liability Valuation (Contd.)   |    |   |        Historical Value   |    |   |        Acquisition Cost   |    |   |        Amount paid initially to acquire the asset.   |    |   |        Includes all costs required to prepare the asset for its intended use.   |    |   |        Examples: Sales tax, shipping, repair and maintenance   |    |   |        Excludes costs to operate the asset.   |    |   |        Historical Value (Contd.)   |    |   |        Adjusted Acquisition Cost   |    |   |        Service potential is consumed gradually or immediately.   |    |   |        The asset is reduced and an expense is increased.   |    |   |        Examples: Buildings, equipment and other depreciable assets, intangibles with limited lives.   |    |     |   |        Historical Value (Contd.)   |    |   |        Initial Present Value   |    |   |        Monetary asset or liability.   |    |   |        Present value computation uses appropriate interest rates .   |    |   |        Examples: Investments in bonds held to maturity, long-term receivables and payables, noncurrent unearned revenue, current receivables and payables.   |    |   |        Current Values   |    |   |        Fair Value   |    |   |        FASB - Exit Price; IASB - Exit or Entry Price    |    |   |        Obtaining the right price - Different Sources of Fair value estimates (3-Tier Hierarchy) described in SFAS No.157 and IFRS No.7    |    |   |        Examples:    |    |   |        Investments in marketable equity and debt securities    |    |   |        Financial instruments and derivative instruments    |    |   |        Fair Value    |    |   |        Income Recognition   |    |   |        Recognition   ‚Üí   Making an entry to record a transaction or an event.   |    |   |        In real world,  all changes in the economic value of a firm  are   not   reflected.   |    |   |        Reporting cash inflows and outflows is   reliable   but is often   not     relevant   for predicting future cash flows.   |    |   |        |    |   |       |                             \n",
       "1172                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            CHAPTER 3 LEARNING OBJECTIVES:     |   Consolidations - Subsequent to the Date of Acquisition      |      |    |     |      |      LO1    |     Recognize the complexities in preparing consolidated financial reports that emerge from the passage of time.   |      |      |      LO2    |     Identify and describe the various methods available to a parent company in order to maintain its investment in subsidiary account in its internal records.   |      |      |      LO3    |     Understand that a parent's internal accounting method for its subsidiary investments has no effect on the resulting consolidated financial statements.   |      |      |      LO4    |     Prepare consolidated financial statements subsequent to acquisition when the parent has applied in its internal records: |        |       The equity method.   |       The initial value method.   |       The partial equity method.   |         |      |      |      LO5    |     Discuss the rationale for the goodwill impairment testing approach.   |      |      |      LO6    |     Describe the procedures for conducting a goodwill impairment test.   |      |      |      LO7    |     Understand the accounting and reporting for contingent consideration subsequent to a business acquisition.   |      |      |      LO8    |     Understand in general the requirements of pushdown accounting and when its use is appropriate.   |      |     |    |      |    CHAPTER 4 LEARNING OBJECTIVES     |   Consolidated Financial Statements and Outside Ownership    |      |    |     |      |      LO1    |     Understand that complete ownership is not a prerequisite for the formation of a business combination.   |      |      |      LO2    |     Describe the valuation principles underlying the acquisition method of accounting for the noncontrolling interest.   |      |      |      LO3    |     Allocate goodwill acquired in a business combination across the controlling and noncontrolling interests.   |      |      |      LO4    |     Understand the computation and allocation of consolidated net income in the presence of a noncontrolling interest.   |      |      |      LO5    |     Identify and calculate the four noncontrolling interest figures that must be included within the consolidation process and prepare a consolidation worksheet in the presence of a noncontrolling interest.   |      |      |      LO6    |     Identify appropriate placements for the components of the noncontrolling interest in consolidated financial statements.   |      |      |      LO7    |     Determine the effect on consolidated financial statements of a control premium paid by the parent.   |      |      |      LO8    |     Understand the impact on consolidated financial statements of a midyear acquisition.   |      |      |      LO9    |     Understand the impact on consolidated financial statements when a step acquisition has taken place.   |      |      |      LO10    |     Record the sale of a subsidiary (or a portion of its shares).   |      |     |    |      |                              \n",
       "1174                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   CHAPTER 7 LEARNING OBJECTIVES:     |   Consolidated Financial Statements - Ownership Patterns and Income Taxes    |    |     |      |      LO1    |     Understand the implications for the consolidation process when indirect control is present in a grandfather-father-son ownership configuration.   |      |      |      LO2    |     Understand the implications for the consolidation process when a corporate ownership structure is characterized by a connecting affiliation.   |      |      |      LO3    |     Understand the implications for the consolidation process when a corporate ownership structure is characterized by mutual ownership.   |      |      |      LO4    |       List the criteria for being a member of an affiliated group for income tax filing purposes.     |      |      |      LO5    |       Compute taxable income and deferred tax amounts for an affiliated group based on information presented in a consolidated set of financial statements.     |      |      |      LO6    |       Compute taxable income and deferred tax amounts to be recognized when separate tax returns are filed by any of the affiliates of a business combination.     |      |      |      LO7    |       Determine the deferred tax consequences for temporary differences generated when a business combination is created.     |      |      |      LO8    |       Explain the impact that a net operating loss of an acquired affiliate has on consolidated figures.     |      |     |    |       |       |   CHAPTER 8 LEARNING OBJECTIVES:    |   Segment and Interim Reporting    |    |     |      |      LO1    |       Understand how an enterprise determines its operating segments and the factors that influence this determination.     |      |      |      LO2    |       Apply the three tests that are used to determine which operating segments are of significant size to warrant separate disclosure.     |      |      |      LO3    |     List the basic disclosure requirements for operating segments.   |      |      |      LO4    |       Determine when and what types of information must be disclosed for geographic areas.     |      |      |      LO5    |       Apply the criterion for determining when disclosure of a major customer is required.     |      |      |      LO6    |       Recognize differences between U.S. GAAP and IFRS in segment reporting.     |      |      |      LO7    |       Understand and apply procedures used in interim reports to treat an interim period as an integral part of the annual period.     |      |      |      LO8    |       List the minimum disclosure requirements for interim financial reports.     |      |      |      LO9    |       Recognize differences between U.S. GAAP and IFRS in interim reporting     |      |     |    |                                \n",
       "1177                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CHAPTER 16 LEARNING OBJECTIVES:     |     |    |     |      |      LO 16-1    |     Explain the history of and the reasons for the unique characteristics of the financial statements produced by state and local governments.   |      |      |      LO 16-2    |     Differentiate between the two sets of financial statements produced by state and local governments.   |      |      |      LO 16-3    |     Understand the reason that fund accounting has traditionally been a prominent factor in the internal recording of state and local governments.   |      |      |      LO 16-4    |     Identify the three fund types and the individual fund categories within each.   |      |      |      LO 16-5    |     Understand the basic structure of government-wide financial statements and fund financial statements (as produced for the governmental funds).   |      |      |      LO 16-6    |     Record the passage of a budget as well as subsequent encumbrances and expenditures.   |      |      |      LO 16-7    |     Understand the reporting of capital assets, supplies, and prepaid expenses by a state or local government.   |      |      |      LO 16-8    |     Determine the proper timing for the recognition of revenues from various types of nonexchange transactions.   |      |      |      LO 16-9    |     Account for the issuance of long-term bonds and the reporting of special assessment projects.   |      |      |      LO 16-10    |     Record the various types of monetary transfers that occur within the funds maintained by a state or local government.   |      |     |    |      |      |   CHAPTER 17 LEARNING OBJECTIVES:    |    |     |      |      LO 17-1    |     Account for lease contracts where the state or local government finds itself as either lessor or lessee.   |      |      |      LO 17-2    |     Recognize the liability caused by the eventual closure and postclosure costs of operating a solid waste landfill.   |      |      |      LO 17-3    |     Explain the reporting of a net pension liability resulting from a defined benefit pension plan provided to employees by a state or local government.   |      |      |      LO 17-4    |     Record the donation and acquisition of works of art and historical treasures.   |      |      |      LO 17-5    |     Explain the reporting and possible depreciation of infrastructure assets.   |      |      |      LO 17-6    |     Understand the composition of a state or local government's comprehensive annual financial report (CAFR).   |      |      |      LO 17-7    |     Explain the makeup of a primary government and its relationship to component units and related organizations as well as the combination of governments.   |      |      |      LO 17-8    |     Describe the physical structure of a complete set of government-wide financial statements and a complete set of fund financial statements.   |      |      |      LO 17-9    |     Understand the presentation of financial statements for a public college or university.   |      |     |                             \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ...   \n",
       "53814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     By the end of this module, you will have the opportunity to:    |  |    |  |     |  |    |  |    |  |  |  |  Identify findings specific to normal and |  | pathological pediatric radiographs.  |  |  |  |  Identify and select appropriate |  | modalities for neuro-imaging.   |  |  |  |  Use a systematic approach viewing |  | neuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary |  | pathology viewed on radiographs. |  |  |  |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |     |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin-top:0in; |  |  | mso-para-margin-right:0in; |  |  | mso-para-margin-bottom:10.0pt; |  |  | mso-para-margin-left:0in; |  |  | line-height:115%; |  |  | mso-pagination:widow-orphan; |  |  | font-size:11.0pt; |  |  | font-family:\"Calibri\",\"sans-serif\"; |  |  | mso-ascii-font-family:Calibri; |  |  | mso-ascii-theme-font:minor-latin; |  |  | mso-hansi-font-family:Calibri; |  |  | mso-hansi-theme-font:minor-latin;} |  |   |  |                              \n",
       "56122    |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |                            \n",
       "56134                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |    \n",
       "56182    |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |                            \n",
       "56207                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |    \n",
       "\n",
       "                                                                            los1  \\\n",
       "941      By the end of the week, you will have the opportunity to understand:      \n",
       "1033     By the end of the week, you will have the opportunity to understand:      \n",
       "1172                                          CHAPTER 3 LEARNING OBJECTIVES:       \n",
       "1174                                          CHAPTER 7 LEARNING OBJECTIVES:       \n",
       "1177                                         CHAPTER 16 LEARNING OBJECTIVES:       \n",
       "...                                                                          ...   \n",
       "53814            By the end of this module, you will have the opportunity to:      \n",
       "56122                                                                        NaN   \n",
       "56134                                                                        NaN   \n",
       "56182                                                                        NaN   \n",
       "56207                                                                        NaN   \n",
       "\n",
       "      los2  \\\n",
       "941     |    \n",
       "1033    |    \n",
       "1172    |    \n",
       "1174    |    \n",
       "1177    |    \n",
       "...    ...   \n",
       "53814   |    \n",
       "56122   |    \n",
       "56134   |    \n",
       "56182   |    \n",
       "56207   |    \n",
       "\n",
       "                                                                               los3  \\\n",
       "941                                                                             NaN   \n",
       "1033                                                                            NaN   \n",
       "1172                    Consolidations - Subsequent to the Date of Acquisition        \n",
       "1174     Consolidated Financial Statements - Ownership Patterns and Income Taxes      \n",
       "1177                                                                            NaN   \n",
       "...                                                                             ...   \n",
       "53814                                                                           NaN   \n",
       "56122                                                                           NaN   \n",
       "56134                                                                           NaN   \n",
       "56182                                                                           NaN   \n",
       "56207                                                                           NaN   \n",
       "\n",
       "      los4 los5 los6  ... los780 los781 los782 los783 los784 los785 los786  \\\n",
       "941     |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "1033    |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "1172    |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "1174    |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "1177    |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "...    ...  ...  ...  ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "53814   |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "56122   |   NaN   |   ...     |     NaN     |     NaN     |     NaN     |    \n",
       "56134   |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "56182   |   NaN   |   ...     |     NaN     |     NaN     |     NaN     |    \n",
       "56207   |   NaN   |   ...   None   None   None    NaN   None    NaN   None   \n",
       "\n",
       "      los787 los788 los789  \n",
       "941     None   None    NaN  \n",
       "1033    None   None    NaN  \n",
       "1172    None   None    NaN  \n",
       "1174    None   None    NaN  \n",
       "1177    None   None    NaN  \n",
       "...      ...    ...    ...  \n",
       "53814   None   None    NaN  \n",
       "56122      \"     |     NaN  \n",
       "56134   None   None    NaN  \n",
       "56182      \"     |     NaN  \n",
       "56207   None   None    NaN  \n",
       "\n",
       "[201 rows x 793 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df3[df3['los150'].notnull()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(58897, 793)"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df3.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://stackoverflow.com/questions/23743460/replace-none-with-nan-in-pandas-dataframe\n",
    "df3.dropna(axis=1, how='all', inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(58897, 684)"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df3.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "      <th>los1</th>\n",
       "      <th>los2</th>\n",
       "      <th>los3</th>\n",
       "      <th>los4</th>\n",
       "      <th>los5</th>\n",
       "      <th>los6</th>\n",
       "      <th>...</th>\n",
       "      <th>los776</th>\n",
       "      <th>los777</th>\n",
       "      <th>los778</th>\n",
       "      <th>los780</th>\n",
       "      <th>los781</th>\n",
       "      <th>los782</th>\n",
       "      <th>los784</th>\n",
       "      <th>los786</th>\n",
       "      <th>los787</th>\n",
       "      <th>los788</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>7312</th>\n",
       "      <td>BTC6213</td>\n",
       "      <td>Week 11:  Quality Control Assurance in Clinical Trials: Managing Risks</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Discuss types of risks in clinical trials   \\n   Discuss the general steps to manage risk in clinical trials   \\n   Discuss the recommended approach by both the FDA and EMA on risk management in clinical trials    \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Discuss types of risks in clinical trials    |    Discuss the general steps to manage risk in clinical trials    |    Discuss the recommended approach by both the FDA and EMA on risk management in clinical trials     |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7315</th>\n",
       "      <td>BTC6213</td>\n",
       "      <td>Week 3:  The Informed Consent Process</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n         Describe the process of obtaining informed consent   \\n   Describe the confidentiality protections in place   \\n   List and describe the different groups of  special populations in research  \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |          Describe the process of obtaining informed consent    |    Describe the confidentiality protections in place    |    List and describe the different groups of  special populations in research   |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>Describe the process of obtaining informed consent</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7316</th>\n",
       "      <td>BTC6213</td>\n",
       "      <td>Week 4: Clinical Trial Registries and Natural History in Trial Design</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Describe how natural history and registry data may be useful in clinical trial design   \\n   Describe the type of data collected as part of natural history and registry trials   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |    Describe how natural history and registry data may be useful in clinical trial design    |    Describe the type of data collected as part of natural history and registry trials    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>Describe how natural history and registry data may be useful in clinical trial design</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7317</th>\n",
       "      <td>BTC6213</td>\n",
       "      <td>Week 5:  Trial Design Basics</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Discuss the different types of clinical trial designs along with the advantages / disadvantages   \\n         Determine how to develop a measurable outcome   \\n   Discuss concepts in hypothesis testing and fundamental concepts related to power and sample size calculations   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Discuss the different types of clinical trial designs along with the advantages / disadvantages    |          Determine how to develop a measurable outcome    |    Discuss concepts in hypothesis testing and fundamental concepts related to power and sample size calculations    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7318</th>\n",
       "      <td>BTC6213</td>\n",
       "      <td>Week 7:  Administrative: Technology Transfer, Trial Agreements, Patent Protection and Trial Budgets</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Familiarize the legal nomenclature in the clinical trial landscape   \\n         Appreciate common issues around patent protection and it's relationship to trial agreements   \\n   Consider the various legal issues in context of a trial budget   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Familiarize the legal nomenclature in the clinical trial landscape    |          Appreciate common issues around patent protection and it's relationship to trial agreements    |    Consider the various legal issues in context of a trial budget    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53814</th>\n",
       "      <td>PTH6110</td>\n",
       "      <td>Module 2: Neuroimaging, Cadiopulmonary imaging and Pediatrics</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:   \\r\\n  \\r\\n   \\r\\n  \\r\\n  \\r\\n\\r\\n Identify findings specific to normal and\\r\\npathological pediatric radiographs. \\r\\n\\r\\n Identify and select appropriate\\r\\nmodalities for neuro-imaging.  \\r\\n\\r\\n Use a systematic approach viewing\\r\\nneuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary\\r\\npathology viewed on radiographs.\\r\\n\\r\\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n   \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin-top:0in;\\r\\n\\tmso-para-margin-right:0in;\\r\\n\\tmso-para-margin-bottom:10.0pt;\\r\\n\\tmso-para-margin-left:0in;\\r\\n\\tline-height:115%;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:11.0pt;\\r\\n\\tfont-family:\"Calibri\",\"sans-serif\";\\r\\n\\tmso-ascii-font-family:Calibri;\\r\\n\\tmso-ascii-theme-font:minor-latin;\\r\\n\\tmso-hansi-font-family:Calibri;\\r\\n\\tmso-hansi-theme-font:minor-latin;}\\r\\n \\r\\n</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:    |  |    |  |     |  |    |  |    |  |  |  |  Identify findings specific to normal and |  | pathological pediatric radiographs.  |  |  |  |  Identify and select appropriate |  | modalities for neuro-imaging.   |  |  |  |  Use a systematic approach viewing |  | neuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary |  | pathology viewed on radiographs. |  |  |  |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |     |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin-top:0in; |  |  | mso-para-margin-right:0in; |  |  | mso-para-margin-bottom:10.0pt; |  |  | mso-para-margin-left:0in; |  |  | line-height:115%; |  |  | mso-pagination:widow-orphan; |  |  | font-size:11.0pt; |  |  | font-family:\"Calibri\",\"sans-serif\"; |  |  | mso-ascii-font-family:Calibri; |  |  | mso-ascii-theme-font:minor-latin; |  |  | mso-hansi-font-family:Calibri; |  |  | mso-hansi-theme-font:minor-latin;} |  |   |  |</td>\n",
       "      <td>By the end of this module, you will have the opportunity to:</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56122</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>\"</td>\n",
       "      <td>|</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56134</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56182</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 11: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>|</td>\n",
       "      <td>\"</td>\n",
       "      <td>|</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56207</th>\n",
       "      <td>RGA6223</td>\n",
       "      <td>Week 10: Regulatory Strategy Development China Pharma/Devices Regulation</td>\n",
       "      <td>\\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  &lt;w:</td>\n",
       "      <td>|     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   &lt;w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>|</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>83 rows × 684 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      course_id  \\\n",
       "7312    BTC6213   \n",
       "7315    BTC6213   \n",
       "7316    BTC6213   \n",
       "7317    BTC6213   \n",
       "7318    BTC6213   \n",
       "...         ...   \n",
       "53814   PTH6110   \n",
       "56122   RGA6223   \n",
       "56134   RGA6223   \n",
       "56182   RGA6223   \n",
       "56207   RGA6223   \n",
       "\n",
       "                                                                                                    folder  \\\n",
       "7312                                Week 11:  Quality Control Assurance in Clinical Trials: Managing Risks   \n",
       "7315                                                                 Week 3:  The Informed Consent Process   \n",
       "7316                                 Week 4: Clinical Trial Registries and Natural History in Trial Design   \n",
       "7317                                                                          Week 5:  Trial Design Basics   \n",
       "7318   Week 7:  Administrative: Technology Transfer, Trial Agreements, Patent Protection and Trial Budgets   \n",
       "...                                                                                                    ...   \n",
       "53814                                        Module 2: Neuroimaging, Cadiopulmonary imaging and Pediatrics   \n",
       "56122                             Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56134                             Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56182                             Week 11: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "56207                             Week 10: Regulatory Strategy Development China Pharma/Devices Regulation   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 main_data  \\\n",
       "7312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Discuss types of risks in clinical trials   \\n   Discuss the general steps to manage risk in clinical trials   \\n   Discuss the recommended approach by both the FDA and EMA on risk management in clinical trials    \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n    \n",
       "7315                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:   \\n  \\n         Describe the process of obtaining informed consent   \\n   Describe the confidentiality protections in place   \\n   List and describe the different groups of  special populations in research  \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n    \n",
       "7316                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:   \\n  \\n   Describe how natural history and registry data may be useful in clinical trial design   \\n   Describe the type of data collected as part of natural history and registry trials   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n    \n",
       "7317                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Discuss the different types of clinical trial designs along with the advantages / disadvantages   \\n         Determine how to develop a measurable outcome   \\n   Discuss concepts in hypothesis testing and fundamental concepts related to power and sample size calculations   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n    \n",
       "7318                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         By the end of the week, you will have the opportunity to:   \\n  \\r\\n  \\r\\n   12.00 \\r\\n  \\r\\n   \\n  \\n         Familiarize the legal nomenclature in the clinical trial landscape   \\n         Appreciate common issues around patent protection and it's relationship to trial agreements   \\n   Consider the various legal issues in context of a trial budget   \\n  \\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   MicrosoftInternetExplorer4 \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\n  \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n  \\n \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-qformat:yes;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin:0in;\\r\\n\\tmso-para-margin-bottom:.0001pt;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:10.0pt;\\r\\n\\tfont-family:\"Times New Roman\",\"serif\";}\\r\\n \\r\\n    \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
       "53814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       By the end of this module, you will have the opportunity to:   \\r\\n  \\r\\n   \\r\\n  \\r\\n  \\r\\n\\r\\n Identify findings specific to normal and\\r\\npathological pediatric radiographs. \\r\\n\\r\\n Identify and select appropriate\\r\\nmodalities for neuro-imaging.  \\r\\n\\r\\n Use a systematic approach viewing\\r\\nneuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary\\r\\npathology viewed on radiographs.\\r\\n\\r\\n  \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  \\r\\n   \\r\\n \\r\\n /* Style Definitions */\\r\\n table.MsoNormalTable\\r\\n\\t{mso-style-name:\"Table Normal\";\\r\\n\\tmso-tstyle-rowband-size:0;\\r\\n\\tmso-tstyle-colband-size:0;\\r\\n\\tmso-style-noshow:yes;\\r\\n\\tmso-style-priority:99;\\r\\n\\tmso-style-parent:\"\";\\r\\n\\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\\r\\n\\tmso-para-margin-top:0in;\\r\\n\\tmso-para-margin-right:0in;\\r\\n\\tmso-para-margin-bottom:10.0pt;\\r\\n\\tmso-para-margin-left:0in;\\r\\n\\tline-height:115%;\\r\\n\\tmso-pagination:widow-orphan;\\r\\n\\tfont-size:11.0pt;\\r\\n\\tfont-family:\"Calibri\",\"sans-serif\";\\r\\n\\tmso-ascii-font-family:Calibri;\\r\\n\\tmso-ascii-theme-font:minor-latin;\\r\\n\\tmso-hansi-font-family:Calibri;\\r\\n\\tmso-hansi-theme-font:minor-latin;}\\r\\n \\r\\n     \n",
       "56122   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56134   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56182   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "56207   \\n   \\n  \\n  This week, you will have the opportunity to:    \\n  Describe the main objective and the purpose of the CFDA   \\n  List the key  medical device departments   \\n  Define the key opportunities for the medical device companies to market products in China   \\n  List and describe the key elements of the China healthcare    \\n  List and describe the main difficulties  and opportunities for the med devices as well as drugs in China    \\n  List and define the key regulatory strategies effecting drug companies in China   \\n     \\n  \\n     \\n     \\n        \\n         \\n      \\n  \\n     ¬∑            \\n    Describe the   main objective   and the purpose of the   CFDA   \\n        \\n  \\n       ¬∑             \\n      List key   medical device departments     \\n        \\n  \\n       ¬∑             \\n      Define the key   opportunities for the medical device companies to market products in China     \\n        \\n    \\n      ¬∑            \\n     List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China    \\n        \\n    \\n      ¬∑            \\n     List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China    \\n        \\n    \\n      ¬∑            \\n     List and define the   key regulatory strategies effecting drug companies in China    \\n        \\n  \\n   \\n      \\n     \\n  \\n  \\n \\n  \\n  \\n  \\n  \\n   \\n   \\r\\n  \\r\\n   \\r\\n  \\r\\n   \\n   \\n   \\n   \\r\\n  \\r\\n   Normal \\r\\n   0 \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   false \\r\\n   false \\r\\n   false \\r\\n   \\r\\n   EN-US \\r\\n   X-NONE \\r\\n   X-NONE \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\r\\n   \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n    \\r\\n   \\n   \\r\\n  \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n   \\r\\n  <w:   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      los  \\\n",
       "7312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Discuss types of risks in clinical trials    |    Discuss the general steps to manage risk in clinical trials    |    Discuss the recommended approach by both the FDA and EMA on risk management in clinical trials     |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |                             \n",
       "7315                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you will have the opportunity to:    |    |          Describe the process of obtaining informed consent    |    Describe the confidentiality protections in place    |    List and describe the different groups of  special populations in research   |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |                             \n",
       "7316                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        By the end of the week, you will have the opportunity to:    |    |    Describe how natural history and registry data may be useful in clinical trial design    |    Describe the type of data collected as part of natural history and registry trials    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |                             \n",
       "7317                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Discuss the different types of clinical trial designs along with the advantages / disadvantages    |          Determine how to develop a measurable outcome    |    Discuss concepts in hypothesis testing and fundamental concepts related to power and sample size calculations    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |                             \n",
       "7318                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:    |    |  |    |  |    12.00  |  |    |  |     |    |          Familiarize the legal nomenclature in the clinical trial landscape    |          Appreciate common issues around patent protection and it's relationship to trial agreements    |    Consider the various legal issues in context of a trial budget    |    |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |    MicrosoftInternetExplorer4  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |    |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |    |   |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-qformat:yes; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin:0in; |  |  | mso-para-margin-bottom:.0001pt; |  |  | mso-pagination:widow-orphan; |  |  | font-size:10.0pt; |  |  | font-family:\"Times New Roman\",\"serif\";} |  |   |  |                             \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ...   \n",
       "53814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     By the end of this module, you will have the opportunity to:    |  |    |  |     |  |    |  |    |  |  |  |  Identify findings specific to normal and |  | pathological pediatric radiographs.  |  |  |  |  Identify and select appropriate |  | modalities for neuro-imaging.   |  |  |  |  Use a systematic approach viewing |  | neuro-imaging, identifying pathology and analyzing clinical presentation. Identify common cardiopulmonary |  | pathology viewed on radiographs. |  |  |  |    |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |    |  |     |  |   |  |  /* Style Definitions */ |  |  table.MsoNormalTable |  |  | {mso-style-name:\"Table Normal\"; |  |  | mso-tstyle-rowband-size:0; |  |  | mso-tstyle-colband-size:0; |  |  | mso-style-noshow:yes; |  |  | mso-style-priority:99; |  |  | mso-style-parent:\"\"; |  |  | mso-padding-alt:0in 5.4pt 0in 5.4pt; |  |  | mso-para-margin-top:0in; |  |  | mso-para-margin-right:0in; |  |  | mso-para-margin-bottom:10.0pt; |  |  | mso-para-margin-left:0in; |  |  | line-height:115%; |  |  | mso-pagination:widow-orphan; |  |  | font-size:11.0pt; |  |  | font-family:\"Calibri\",\"sans-serif\"; |  |  | mso-ascii-font-family:Calibri; |  |  | mso-ascii-theme-font:minor-latin; |  |  | mso-hansi-font-family:Calibri; |  |  | mso-hansi-theme-font:minor-latin;} |  |   |  |                              \n",
       "56122    |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |                            \n",
       "56134                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |    \n",
       "56182    |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |                          |          |  |  |  |  |                          |       |  |  |  |                          |       |  |  |  |  |                          |          |  |  |  |  |                          |           |  |  |  |  |                          |        |  |  |  |  |                          |    |  |  |  |  |                          |       ∑             |  |  |  |  |                          |     Describe the   main objective   and the purpose of the   CFDA    |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       List key   medical device departments      |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |         ∑              |  |  |  |  |                          |       Define the key   opportunities for the medical device companies to market products in China      |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |                          |          |  |  |  |  |                          |      |  |  |  |  |                          |        ∑             |  |  |  |  |                          |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |                          |          |  |  |  |  |                          |    |  |  |  |  |                          |    |  |  |  |  |                          |   |  |  |  |  |                          |     |  |  |  |  |                          |     |  |  |  |  |                          |    \" |  |  |  |  |                            \n",
       "56207                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |    |   This week, you will have the opportunity to:     |   Describe the main objective and the purpose of the CFDA    |   List the key  medical device departments    |   Define the key opportunities for the medical device companies to market products in China    |   List and describe the key elements of the China healthcare     |   List and describe the main difficulties  and opportunities for the med devices as well as drugs in China     |   List and define the key regulatory strategies effecting drug companies in China    |       |    |       |       |          |           |        |    |       ∑             |     Describe the   main objective   and the purpose of the   CFDA    |          |    |         ∑              |       List key   medical device departments      |          |    |         ∑              |       Define the key   opportunities for the medical device companies to market products in China      |          |      |        ∑             |      List and describe     the key elements of the China    healthcare    system to other key markets, including     SA     and   China     |          |      |        ∑             |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |          |      |        ∑             |      List and define the   key regulatory strategies effecting drug companies in China     |          |    |     |        |       |    |    |   |    |    |    |    |     |     |  |    |  |     |  |    |  |     |     |     |     |  |    |  |    Normal  |  |    0  |  |     |  |     |  |     |  |     |  |    false  |  |    false  |  |    false  |  |     |  |    EN-US  |  |    X-NONE  |  |    X-NONE  |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |  |     |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |      |  |     |     |  |    |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |     |  |   <w:                           This week you will have the opportunity to:    |  |  |          |  |  |  |  |       |  |  |  |       |  |  |  |  |          |  |  |  |  |           |  |  |  |  |        |  |  |  |  |    |  |  |  |  |       ∑             |  |  |  |  |     Describe the   main objective   and the purpose of the   CFDA    |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       List key   medical device departments      |  |  |          |  |  |  |  |    |  |  |  |  |         ∑              |  |  |  |  |       Define the key   opportunities for the medical device companies to market products in China      |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe     the key elements of the China    healthcare    system to other key markets |  including     SA     and   China     |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and describe the main difficulties   and     opportunities     for the med devices as well as drugs in China     |  |  |          |  |  |  |  |      |  |  |  |  |        ∑             |  |  |  |  |      List and define the   key regulatory strategies effecting drug companies in China     |  |  |          |  |  |  |  |    |  |  |  |  |    |  |  |  |  |   |  |  |  |  |     |  |  |  |  |     |  |  |  |  |    \" |  |  |  |    \n",
       "\n",
       "                                                                   los1 los2  \\\n",
       "7312       By the end of the week, you will have the opportunity to:      |    \n",
       "7315       By the end of the week, you will have the opportunity to:      |    \n",
       "7316       By the end of the week, you will have the opportunity to:      |    \n",
       "7317       By the end of the week, you will have the opportunity to:      |    \n",
       "7318       By the end of the week, you will have the opportunity to:      |    \n",
       "...                                                                 ...  ...   \n",
       "53814   By the end of this module, you will have the opportunity to:      |    \n",
       "56122                                                               NaN   |    \n",
       "56134                                                               NaN   |    \n",
       "56182                                                               NaN   |    \n",
       "56207                                                               NaN   |    \n",
       "\n",
       "      los3 los4  \\\n",
       "7312   NaN   |    \n",
       "7315   NaN   |    \n",
       "7316   NaN   |    \n",
       "7317   NaN   |    \n",
       "7318   NaN   |    \n",
       "...    ...  ...   \n",
       "53814  NaN   |    \n",
       "56122  NaN   |    \n",
       "56134  NaN   |    \n",
       "56182  NaN   |    \n",
       "56207  NaN   |    \n",
       "\n",
       "                                                                                              los5  \\\n",
       "7312                                                                                           NaN   \n",
       "7315                                         Describe the process of obtaining informed consent      \n",
       "7316      Describe how natural history and registry data may be useful in clinical trial design      \n",
       "7317                                                                                           NaN   \n",
       "7318                                                                                           NaN   \n",
       "...                                                                                            ...   \n",
       "53814                                                                                          NaN   \n",
       "56122                                                                                          NaN   \n",
       "56134                                                                                          NaN   \n",
       "56182                                                                                          NaN   \n",
       "56207                                                                                          NaN   \n",
       "\n",
       "      los6  ... los776 los777 los778 los780 los781 los782 los784 los786  \\\n",
       "7312    |   ...   None   None   None   None   None   None   None   None   \n",
       "7315    |   ...   None   None   None   None   None   None   None   None   \n",
       "7316    |   ...   None   None   None   None   None   None   None   None   \n",
       "7317    |   ...   None   None   None   None   None   None   None   None   \n",
       "7318    |   ...   None   None   None   None   None   None   None   None   \n",
       "...    ...  ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "53814   |   ...   None   None   None   None   None   None   None   None   \n",
       "56122   |   ...     |     NaN     |      |     NaN     |      |      |    \n",
       "56134   |   ...   None   None   None   None   None   None   None   None   \n",
       "56182   |   ...     |     NaN     |      |     NaN     |      |      |    \n",
       "56207   |   ...   None   None   None   None   None   None   None   None   \n",
       "\n",
       "      los787 los788  \n",
       "7312    None   None  \n",
       "7315    None   None  \n",
       "7316    None   None  \n",
       "7317    None   None  \n",
       "7318    None   None  \n",
       "...      ...    ...  \n",
       "53814   None   None  \n",
       "56122      \"     |   \n",
       "56134   None   None  \n",
       "56182      \"     |   \n",
       "56207   None   None  \n",
       "\n",
       "[83 rows x 684 columns]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#https://stackoverflow.com/questions/24511200/index-of-non-nan-values-in-pandas\n",
    "df3[df3['los400'].notnull()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "df3.drop(['los'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "#sandbox "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "df4 = df3.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://cmdlinetips.com/2019/06/reshaping-dataframes-with-pandas-melt-and-wide_to_long/\n",
    "#df_melt = df4.loc[:, df4.columns.str.contains('^los|^c|^f|^m')]\n",
    "#print(df_melt.head(n=3))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "final = df4.melt(id_vars=[\"course_id\",\"folder\",\"main_data\"], \n",
    "                              var_name=\"los\", \n",
    "                              value_name=\"var\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "      <th>var</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 10: Long Lived Assets</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   understand how to account for long lived assets  \\n   understand how to fund and depreciate long lived assets  \\n   understand how the funding and depreciation method of a long lived asset affects cash flows  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 11: Liabilities</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   understand the liability accounts  \\n  review the recording of liability entries  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 12: Shareholder's Equity (SHE)</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   learn how to journalize SHE  \\n  understand why the Retained Earnings Statement became a require financial statement  \\n  recognize how the IS and BS are used to flow into the Cash Flow statement  \\n  understand how the IS and BS influence the Retained Earnings  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 13: Statement of Cash Flows</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 14: The Big Picture (Analysis)</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   work with various analytical tools  \\n  understand the difference between Accounting and analysis  \\n  review the financial ratios used by accountants an financial analysts  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Introduction to Financial Statements</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   be introduced to financial statements (Balance Sheet, Income Statement, Cash Flow Statement and Retained earnings Statement)  \\n  learn the purpose of each of the statements  \\n  understand the interdependence of the statements  \\n   recognize the role of an accountant  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2: More on Financial Statements</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 3: The Accounting Information System</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   learn how accounting provides information about a financial event  \\n  recognize what a Dr. and a Cr. is and how they are presented in a journal entry (JE)  \\n  understand the purpose and importance of a General Ledger (GL)  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 4: Accrual Accounting</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   learn the uses of accrual accounting  \\n  understand how accrual entries have made accounting more relevant  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 5: The Income Statement</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   recognize the form of an IS  \\n  understand how to create an IS  \\n  understand the order in which financial statements should be completed  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 6: Inventory</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   understand the complexities of inventory accounting  \\n  recognize that retail and manufacturing inventory accounting are very different  \\n  learn how to journalize inventory transactions  \\n  understand raw material, work-in-progress and finished goods inventory  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 7: Fraud and Internal Control</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   ASK QUESTIONS BEFORE THE MID TERM EXAM  \\n  review the state of fraud prevention in corporate America  \\n  understand why cash is a sensative item among asset management  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 9: Receivables</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   understand the JEs for AR  \\n  understand the importance of a bad debt reserve and how to calculate the correct balance for bad debt  \\n   understand the interactions between revenue and AR  \\n   recognize what DSO means and how to calculate the DSO  \\n   understand the importance of AR decisions  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Online - Week 10: Read and Study Chapter 9 Reporting and Analyzing Long-Lived Assets</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n    Explain the accounting for plant asset expenditures    \\n    Apply depreciation methods to plant assets    \\n    Explain how to account for the disposal of plant assets    \\n    Identify the basic issues related to reporting intangible assets    \\n    Discuss how long-lived assets are reported and analyzed.    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Online - Week 11: Read and Study Chapter 10 Reporting and Analyzing Liabilities</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Explain how to account for current liabilities   \\n    Describe the major characteristics of bonds    \\n    Explain how to account for bond transactions    \\n   Discuss how liabilities are reported and analyzed   \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Online - Week 12: Read and Study Chapter 11 Reporting and Analyzing Stockholders' Equity</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss the major characteristics of a corporation.   \\n    Explain how to account for the issuance of common and preferred stock, and the purchase of treasury stock.    \\n    Explain how to account for cash dividends and describe the effect of stock dividends and stock splits.    \\n    Discuss how stockholders' equity is reported and analyzed.    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Online - Week 13: Read and Study Chapter 12 Statement of Cash Flows</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss the usefulness and format of the statement of cash flows.   \\n   Prepare a statement of cash flows using the indirect method.   \\n   Use the statement of cash flows to evaluate a company.   \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Online - Week 14:  Read and Study Chapter 13 Financial Analysis: The Big Picture</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n    Apply the concepts of sustainable income and quality of earnings.    \\n    Apply horizontal analysis and vertical analysis.    \\n    Analyze a company's performance using ratio analysis.    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Introduction to Financial Statements, Chapter 1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Identify the forms of business organization and the uses of accounting information.   \\n     Explain the three principal types of business activity.   \\n     Describe the four financial statements and how they are prepared.   \\n  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2: A Further Look at Financial Statements, Chapter 2</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n     Identify the sections of a classified balance sheet.   \\n     Use ratios to evaluate a company's profitability, liquidity, and solvency.   \\n     Discuss financial reporting concepts.   \\n  \\n      \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 3: The Accounting Information System, Chapter 3</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n      Learn the effect of business transactions on the basic accounting equation.    \\n      Explain how accounts, debits, and credits are used to record business transactions.    \\n      Indicate how a journal is used in the recording process.    \\n      Explain how a ledger and posting help in the recording process.    \\n   Prepare a trial balance.   \\n  \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 4: Accrual Accounting Concepts, Chapter 4</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Explain the accrual basis of accounting and the reasons for adjusting entries.   \\n            Prepare adjusting entries for deferrals.    \\n      Prepare adjusting entries for accruals.    \\n   Prepare an adjusted trial balance and closing entries.   \\n  \\n      \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 5: Merchandising Operations and the Multiple-Step Income Statement, Chapter 5</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n     Describe merchandising operations and inventory systems.   \\n      Record purchases under a perpetual inventory system.    \\n      Record sales under a perpetual inventory system.    \\n      Prepare a multiple-step income statement and a comprehensive income statement.    \\n  \\n      \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 6: Reporting and Analyzing Inventory, Chapter 6</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss how to classify and determine inventory.   \\n     Apply inventory cost flow methods and discuss their financial effects.      \\n    Explain the statement presentation and analysis of inventory.    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 7: Fraud, Internal Control, and Cash, Chapter 7</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:    \\n  \\n    Define fraud and the principles of internal control.    \\n    Apply internal control principles to cash.    \\n    Identify the control features of a bank account.    \\n    Explain the reporting of cash and the basic principles of cash management.    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 9: Reporting and Analyzing Receivables, Chapter 8</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:   \\n  \\n     Explain how companies recognize accounts receivable.   \\n      Describe how companies value accounts receivable and record their disposition.    \\n      Explain how companies recognize, value, and dispose of notes receivable.    \\n      Describe the statement presentation of receivables and the principles of receivables management.    \\n  \\n    \\n</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   course_id  \\\n",
       "0    ACC2100   \n",
       "1    ACC2100   \n",
       "2    ACC2100   \n",
       "3    ACC2100   \n",
       "4    ACC2100   \n",
       "5    ACC2100   \n",
       "6    ACC2100   \n",
       "7    ACC2100   \n",
       "8    ACC2100   \n",
       "9    ACC2100   \n",
       "10   ACC2100   \n",
       "11   ACC2100   \n",
       "12   ACC2100   \n",
       "13   ACC2100   \n",
       "14   ACC2100   \n",
       "15   ACC2100   \n",
       "16   ACC2100   \n",
       "17   ACC2100   \n",
       "18   ACC2100   \n",
       "19   ACC2100   \n",
       "20   ACC2100   \n",
       "21   ACC2100   \n",
       "22   ACC2100   \n",
       "23   ACC2100   \n",
       "24   ACC2100   \n",
       "25   ACC2100   \n",
       "26   ACC2100   \n",
       "27   ACC2100   \n",
       "28   ACC2100   \n",
       "29   ACC2100   \n",
       "\n",
       "                                                                                      folder  \\\n",
       "0                                                             Week 1: Name weekly topic here   \n",
       "1                                                                                    Week 2:   \n",
       "2                                                             Week 1: Name weekly topic here   \n",
       "3                                                                                    Week 2:   \n",
       "4                                                                 Week 10: Long Lived Assets   \n",
       "5                                                                       Week 11: Liabilities   \n",
       "6                                                        Week 12: Shareholder's Equity (SHE)   \n",
       "7                                                           Week 13: Statement of Cash Flows   \n",
       "8                                                        Week 14: The Big Picture (Analysis)   \n",
       "9                                               Week 1: Introduction to Financial Statements   \n",
       "10                                                      Week 2: More on Financial Statements   \n",
       "11                                                 Week 3: The Accounting Information System   \n",
       "12                                                                Week 4: Accrual Accounting   \n",
       "13                                                              Week 5: The Income Statement   \n",
       "14                                                                         Week 6: Inventory   \n",
       "15                                                        Week 7: Fraud and Internal Control   \n",
       "16                                                                       Week 9: Receivables   \n",
       "17      Online - Week 10: Read and Study Chapter 9 Reporting and Analyzing Long-Lived Assets   \n",
       "18           Online - Week 11: Read and Study Chapter 10 Reporting and Analyzing Liabilities   \n",
       "19  Online - Week 12: Read and Study Chapter 11 Reporting and Analyzing Stockholders' Equity   \n",
       "20                       Online - Week 13: Read and Study Chapter 12 Statement of Cash Flows   \n",
       "21          Online - Week 14:  Read and Study Chapter 13 Financial Analysis: The Big Picture   \n",
       "22                                   Week 1: Introduction to Financial Statements, Chapter 1   \n",
       "23                                 Week 2: A Further Look at Financial Statements, Chapter 2   \n",
       "24                                      Week 3: The Accounting Information System, Chapter 3   \n",
       "25                                            Week 4: Accrual Accounting Concepts, Chapter 4   \n",
       "26        Week 5: Merchandising Operations and the Multiple-Step Income Statement, Chapter 5   \n",
       "27                                      Week 6: Reporting and Analyzing Inventory, Chapter 6   \n",
       "28                                      Week 7: Fraud, Internal Control, and Cash, Chapter 7   \n",
       "29                                    Week 9: Reporting and Analyzing Receivables, Chapter 8   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                           main_data  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:        \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:        \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:        \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:        \n",
       "4                                                                                                                                                          By the end of the week, you will have the opportunity to:   \\n  \\n   understand how to account for long lived assets  \\n   understand how to fund and depreciate long lived assets  \\n   understand how the funding and depreciation method of a long lived asset affects cash flows  \\n    \n",
       "5                                                                                                                                                                                                                                                                                         By the end of the week, you will have the opportunity to:   \\n  \\n   understand the liability accounts  \\n  review the recording of liability entries  \\n    \n",
       "6                                                                                                    By the end of the week, you will have the opportunity to:   \\n  \\n   learn how to journalize SHE  \\n  understand why the Retained Earnings Statement became a require financial statement  \\n  recognize how the IS and BS are used to flow into the Cash Flow statement  \\n  understand how the IS and BS influence the Retained Earnings  \\n    \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                     By the end of the week, you will have the opportunity to:        \n",
       "8                                                                                                                                                                                             By the end of the week, you will have the opportunity to:   \\n  \\n   work with various analytical tools  \\n  understand the difference between Accounting and analysis  \\n  review the financial ratios used by accountants an financial analysts  \\n    \n",
       "9                                                                                            By the end of the week, you will have the opportunity to:   \\n  \\n   be introduced to financial statements (Balance Sheet, Income Statement, Cash Flow Statement and Retained earnings Statement)  \\n  learn the purpose of each of the statements  \\n  understand the interdependence of the statements  \\n   recognize the role of an accountant  \\n    \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                    By the end of the week, you will have the opportunity to:        \n",
       "11                                                                                                                                         By the end of the week, you will have the opportunity to:   \\n  \\n   learn how accounting provides information about a financial event  \\n  recognize what a Dr. and a Cr. is and how they are presented in a journal entry (JE)  \\n  understand the purpose and importance of a General Ledger (GL)  \\n    \n",
       "12                                                                                                                                                                                                                                                             By the end of the week, you will have the opportunity to:   \\n  \\n   learn the uses of accrual accounting  \\n  understand how accrual entries have made accounting more relevant  \\n    \n",
       "13                                                                                                                                                                                                                             By the end of the week, you will have the opportunity to:   \\n  \\n   recognize the form of an IS  \\n  understand how to create an IS  \\n  understand the order in which financial statements should be completed  \\n    \n",
       "14                                                                                                By the end of the week, you will have the opportunity to:   \\n  \\n   understand the complexities of inventory accounting  \\n  recognize that retail and manufacturing inventory accounting are very different  \\n  learn how to journalize inventory transactions  \\n  understand raw material, work-in-progress and finished goods inventory  \\n    \n",
       "15                                                                                                                                                                                               By the end of the week, you will have the opportunity to:   \\n  \\n   ASK QUESTIONS BEFORE THE MID TERM EXAM  \\n  review the state of fraud prevention in corporate America  \\n  understand why cash is a sensative item among asset management  \\n    \n",
       "16                                                               By the end of the week, you will have the opportunity to:   \\n  \\n   understand the JEs for AR  \\n  understand the importance of a bad debt reserve and how to calculate the correct balance for bad debt  \\n   understand the interactions between revenue and AR  \\n   recognize what DSO means and how to calculate the DSO  \\n   understand the importance of AR decisions  \\n    \n",
       "17                                                 By the end of the week, you will have the opportunity to:   \\n  \\n    Explain the accounting for plant asset expenditures    \\n    Apply depreciation methods to plant assets    \\n    Explain how to account for the disposal of plant assets    \\n    Identify the basic issues related to reporting intangible assets    \\n    Discuss how long-lived assets are reported and analyzed.    \\n    \n",
       "18                                                                                                                                                     By the end of the week, you will have the opportunity to:   \\n  \\n   Explain how to account for current liabilities   \\n    Describe the major characteristics of bonds    \\n    Explain how to account for bond transactions    \\n   Discuss how liabilities are reported and analyzed   \\n    \n",
       "19            By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss the major characteristics of a corporation.   \\n    Explain how to account for the issuance of common and preferred stock, and the purchase of treasury stock.    \\n    Explain how to account for cash dividends and describe the effect of stock dividends and stock splits.    \\n    Discuss how stockholders' equity is reported and analyzed.    \\n    \n",
       "20                                                                                                                                                                    By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss the usefulness and format of the statement of cash flows.   \\n   Prepare a statement of cash flows using the indirect method.   \\n   Use the statement of cash flows to evaluate a company.   \\n    \n",
       "21                                                                                                                                                                           By the end of the week, you will have the opportunity to:   \\n  \\n    Apply the concepts of sustainable income and quality of earnings.    \\n    Apply horizontal analysis and vertical analysis.    \\n    Analyze a company's performance using ratio analysis.    \\n    \n",
       "22                                                                                                                                By the end of the week, you will have the opportunity to:   \\n  \\n   Identify the forms of business organization and the uses of accounting information.   \\n     Explain the three principal types of business activity.   \\n     Describe the four financial statements and how they are prepared.   \\n  \\n        \n",
       "23                                                                                                                                                            By the end of the week, you will have the opportunity to:   \\n  \\n     Identify the sections of a classified balance sheet.   \\n     Use ratios to evaluate a company's profitability, liquidity, and solvency.   \\n     Discuss financial reporting concepts.   \\n  \\n      \\n          \n",
       "24    By the end of the week, you will have the opportunity to:   \\n  \\n      Learn the effect of business transactions on the basic accounting equation.    \\n      Explain how accounts, debits, and credits are used to record business transactions.    \\n      Indicate how a journal is used in the recording process.    \\n      Explain how a ledger and posting help in the recording process.    \\n   Prepare a trial balance.   \\n  \\n      \n",
       "25                                                                                                By the end of the week, you will have the opportunity to:   \\n  \\n   Explain the accrual basis of accounting and the reasons for adjusting entries.   \\n            Prepare adjusting entries for deferrals.    \\n      Prepare adjusting entries for accruals.    \\n   Prepare an adjusted trial balance and closing entries.   \\n  \\n      \\n      \n",
       "26                                                                         By the end of the week, you will have the opportunity to:   \\n  \\n     Describe merchandising operations and inventory systems.   \\n      Record purchases under a perpetual inventory system.    \\n      Record sales under a perpetual inventory system.    \\n      Prepare a multiple-step income statement and a comprehensive income statement.    \\n  \\n      \\n      \n",
       "27                                                                                                                                                             By the end of the week, you will have the opportunity to:   \\n  \\n   Discuss how to classify and determine inventory.   \\n     Apply inventory cost flow methods and discuss their financial effects.      \\n    Explain the statement presentation and analysis of inventory.    \\n    \n",
       "28                                                                                                              By the end of the week, you will have the opportunity to:    \\n  \\n    Define fraud and the principles of internal control.    \\n    Apply internal control principles to cash.    \\n    Identify the control features of a bank account.    \\n    Explain the reporting of cash and the basic principles of cash management.    \\n    \n",
       "29           By the end of the week, you will have the opportunity to:   \\n  \\n     Explain how companies recognize accounts receivable.   \\n      Describe how companies value accounts receivable and record their disposition.    \\n      Explain how companies recognize, value, and dispose of notes receivable.    \\n      Describe the statement presentation of receivables and the principles of receivables management.    \\n  \\n    \\n      \n",
       "\n",
       "     los  \\\n",
       "0   los1   \n",
       "1   los1   \n",
       "2   los1   \n",
       "3   los1   \n",
       "4   los1   \n",
       "5   los1   \n",
       "6   los1   \n",
       "7   los1   \n",
       "8   los1   \n",
       "9   los1   \n",
       "10  los1   \n",
       "11  los1   \n",
       "12  los1   \n",
       "13  los1   \n",
       "14  los1   \n",
       "15  los1   \n",
       "16  los1   \n",
       "17  los1   \n",
       "18  los1   \n",
       "19  los1   \n",
       "20  los1   \n",
       "21  los1   \n",
       "22  los1   \n",
       "23  los1   \n",
       "24  los1   \n",
       "25  los1   \n",
       "26  los1   \n",
       "27  los1   \n",
       "28  los1   \n",
       "29  los1   \n",
       "\n",
       "                                                                                        var  \n",
       "0    By the end of the week, you will have the opportunity to:                               \n",
       "1    By the end of the week, you will have the opportunity to:                               \n",
       "2    By the end of the week, you will have the opportunity to:                               \n",
       "3    By the end of the week, you will have the opportunity to:                               \n",
       "4                              By the end of the week, you will have the opportunity to:     \n",
       "5                              By the end of the week, you will have the opportunity to:     \n",
       "6                              By the end of the week, you will have the opportunity to:     \n",
       "7    By the end of the week, you will have the opportunity to:                               \n",
       "8                              By the end of the week, you will have the opportunity to:     \n",
       "9                              By the end of the week, you will have the opportunity to:     \n",
       "10   By the end of the week, you will have the opportunity to:                               \n",
       "11                             By the end of the week, you will have the opportunity to:     \n",
       "12                             By the end of the week, you will have the opportunity to:     \n",
       "13                             By the end of the week, you will have the opportunity to:     \n",
       "14                             By the end of the week, you will have the opportunity to:     \n",
       "15                             By the end of the week, you will have the opportunity to:     \n",
       "16                             By the end of the week, you will have the opportunity to:     \n",
       "17                             By the end of the week, you will have the opportunity to:     \n",
       "18                             By the end of the week, you will have the opportunity to:     \n",
       "19                             By the end of the week, you will have the opportunity to:     \n",
       "20                             By the end of the week, you will have the opportunity to:     \n",
       "21                             By the end of the week, you will have the opportunity to:     \n",
       "22                             By the end of the week, you will have the opportunity to:     \n",
       "23                             By the end of the week, you will have the opportunity to:     \n",
       "24                             By the end of the week, you will have the opportunity to:     \n",
       "25                             By the end of the week, you will have the opportunity to:     \n",
       "26                             By the end of the week, you will have the opportunity to:     \n",
       "27                             By the end of the week, you will have the opportunity to:     \n",
       "28                            By the end of the week, you will have the opportunity to:      \n",
       "29                             By the end of the week, you will have the opportunity to:     "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final.head(n=30)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>main_data</th>\n",
       "      <th>los</th>\n",
       "      <th>var</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>40049955</th>\n",
       "      <td>_TEMPL</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los788</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40049956</th>\n",
       "      <td>_TEMPL</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los788</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40049957</th>\n",
       "      <td>_TEMPL</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los788</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40049958</th>\n",
       "      <td>_TEMPL</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los788</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40049959</th>\n",
       "      <td>_TEMPL</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "      <td>los788</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         course_id                          folder  \\\n",
       "40049955    _TEMPL                         Week 2:   \n",
       "40049956    _TEMPL  Week 1: Name weekly topic here   \n",
       "40049957    _TEMPL                         Week 2:   \n",
       "40049958    _TEMPL  Week 1: Name weekly topic here   \n",
       "40049959    _TEMPL                         Week 2:   \n",
       "\n",
       "                                                                main_data  \\\n",
       "40049955   By the end of the week, you will have the opportunity to:        \n",
       "40049956   By the end of the week, you will have the opportunity to:        \n",
       "40049957   By the end of the week, you will have the opportunity to:        \n",
       "40049958   By the end of the week, you will have the opportunity to:        \n",
       "40049959   By the end of the week, you will have the opportunity to:        \n",
       "\n",
       "             los   var  \n",
       "40049955  los788  None  \n",
       "40049956  los788  None  \n",
       "40049957  los788  None  \n",
       "40049958  los788  None  \n",
       "40049959  los788  None  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final.tail(n=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "#pd.set_option(\"display.max_rows\", None, \"display.max_columns\", None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(40049960, 5)"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "#df4 = df3.columns.difference(['genres'])\n",
    "#genres = df['genres'].str.split('|')\n",
    "\n",
    "#df =  (df.loc[df.index.repeat(genres.str.len()), cols]\n",
    "         #.assign(genres=list(chain.from_iterable(genres.tolist()))))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://stackoverflow.com/questions/50098113/convert-columns-into-multiple-rows-in-pandas-dataframe\n",
    "#https://stackoverflow.com/questions/50731229/split-cell-into-multiple-rows-in-pandas-dataframe\n",
    "#https://towardsdatascience.com/reshape-pandas-dataframe-with-melt-in-python-tutorial-and-visualization-29ec1450bb02\n",
    "#df4 = pd.melt(frame=df3,id_vars=['course_id','folder','main_data','los'],var_name='los_list')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-35-07f1906b6ab4>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mfinal\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mto_csv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'clean_los_kc.csv'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/core/generic.py\u001b[0m in \u001b[0;36mto_csv\u001b[0;34m(self, path_or_buf, sep, na_rep, float_format, columns, header, index, index_label, mode, encoding, compression, quoting, quotechar, line_terminator, chunksize, date_format, doublequote, escapechar, decimal, errors)\u001b[0m\n\u001b[1;32m   3165\u001b[0m             \u001b[0mdecimal\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdecimal\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3166\u001b[0m         )\n\u001b[0;32m-> 3167\u001b[0;31m         \u001b[0mformatter\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msave\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3168\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3169\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mpath_or_buf\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/io/formats/csvs.py\u001b[0m in \u001b[0;36msave\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    204\u001b[0m             )\n\u001b[1;32m    205\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 206\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_save\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    207\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    208\u001b[0m         \u001b[0;32mfinally\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/io/formats/csvs.py\u001b[0m in \u001b[0;36m_save\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    326\u001b[0m                 \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    327\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 328\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_save_chunk\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mstart_i\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mend_i\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    329\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    330\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_save_chunk\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstart_i\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mint\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mend_i\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mint\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m->\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/io/formats/csvs.py\u001b[0m in \u001b[0;36m_save_chunk\u001b[0;34m(self, start_i, end_i)\u001b[0m\n\u001b[1;32m    357\u001b[0m             \u001b[0mdecimal\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdecimal\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    358\u001b[0m             \u001b[0mdate_format\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdate_format\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 359\u001b[0;31m             \u001b[0mquoting\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mquoting\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    360\u001b[0m         )\n\u001b[1;32m    361\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mto_native_types\u001b[0;34m(self, slicer, **kwargs)\u001b[0m\n\u001b[1;32m    974\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mslicer\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    975\u001b[0m             \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mvalues\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mslicer\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 976\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mvalues\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_format_native_types\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    977\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    978\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_format_native_types\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mna_rep\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mquoting\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.7/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36m_format_native_types\u001b[0;34m(self, na_rep, quoting, **kwargs)\u001b[0m\n\u001b[1;32m    982\u001b[0m         \u001b[0mmask\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0misna\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    983\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mis_object\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mquoting\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 984\u001b[0;31m             \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0masarray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mastype\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    985\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    986\u001b[0m             \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0marray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdtype\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mobject\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "#final.to_csv('clean_los_kc.csv') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_snippet = final.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_snippet.drop(['main_data'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_head = final_snippet.head(n=200)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>course_id</th>\n",
       "      <th>folder</th>\n",
       "      <th>los</th>\n",
       "      <th>var</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 10: Long Lived Assets</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 1: Name weekly topic here</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>ACC2100</td>\n",
       "      <td>Week 2:</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you will have the opportunity to:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>ACC2200</td>\n",
       "      <td>Week 10: Budgetary Planning &amp; Control</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you should be able to:      Identify the budgets that comprise the Master Budget   Indicate the benefits of budgeting  State the essentials of effective budgeting  Prepare a Sales Budget, Production Budget, Direct Materials   Direct Labor Budget</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>ACC2200</td>\n",
       "      <td>Week 11: Responsibility Accounting</td>\n",
       "      <td>los1</td>\n",
       "      <td>By the end of the week, you should be able to:      Evaluate the usefulness of static budget reports.    Explain the development of flexible budgets  Describe the concept of responsibility accounting   Indicate the features and of cost centers, profit centers, and investment centers</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   course_id                                 folder   los  \\\n",
       "0    ACC2100         Week 1: Name weekly topic here  los1   \n",
       "1    ACC2100                                Week 2:  los1   \n",
       "2    ACC2100         Week 1: Name weekly topic here  los1   \n",
       "3    ACC2100                                Week 2:  los1   \n",
       "4    ACC2100             Week 10: Long Lived Assets  los1   \n",
       "..       ...                                    ...   ...   \n",
       "95   ACC2100                                Week 2:  los1   \n",
       "96   ACC2100         Week 1: Name weekly topic here  los1   \n",
       "97   ACC2100                                Week 2:  los1   \n",
       "98   ACC2200  Week 10: Budgetary Planning & Control  los1   \n",
       "99   ACC2200     Week 11: Responsibility Accounting  los1   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                       var  \n",
       "0                                                                                                                                                                                                                                   By the end of the week, you will have the opportunity to:                               \n",
       "1                                                                                                                                                                                                                                   By the end of the week, you will have the opportunity to:                               \n",
       "2                                                                                                                                                                                                                                   By the end of the week, you will have the opportunity to:                               \n",
       "3                                                                                                                                                                                                                                   By the end of the week, you will have the opportunity to:                               \n",
       "4                                                                                                                                                                                                                                                             By the end of the week, you will have the opportunity to:     \n",
       "..                                                                                                                                                                                                                                                                                                                     ...  \n",
       "95                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:                               \n",
       "96                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:                               \n",
       "97                                                                                                                                                                                                                                  By the end of the week, you will have the opportunity to:                               \n",
       "98                 By the end of the week, you should be able to:      Identify the budgets that comprise the Master Budget   Indicate the benefits of budgeting  State the essentials of effective budgeting  Prepare a Sales Budget, Production Budget, Direct Materials   Direct Labor Budget                            \n",
       "99   By the end of the week, you should be able to:      Evaluate the usefulness of static budget reports.    Explain the development of flexible budgets  Describe the concept of responsibility accounting   Indicate the features and of cost centers, profit centers, and investment centers                            \n",
       "\n",
       "[100 rows x 4 columns]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_head"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(40049960, 4)"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_snippet.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_head.to_csv('clean_los_head_kc.csv') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
